var title_f2_7_2160="Apical 4 chamber normal motion";
var content_f2_7_2160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/58266/Apical_4chamb_norm_movie.mp4?title=Apical+4+chamber+normal+motion\" style=\"width:496px;height:320px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Apical 4 chamber view with normal cardiac motion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This video clip shows normal cardiac motion as seen from an apical four chamber view.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2160=[""].join("\n");
var outline_f2_7_2160=null;
var title_f2_7_2161="Chorionic villus sampling";
var content_f2_7_2161=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chorionic villus sampling (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/7/2161/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2161/contributors\" id=\"au4927\">",
"       Alessandro Ghidini, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/7/2161/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2161/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/7/2161/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2161/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/7/2161?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Chorionic villus sampling (CVS) is a procedure that may be performed during pregnancy to diagnose certain genetic or chromosomal disorders. CVS involves having a biopsy of the developing placenta. The chorionic villi are the tiny units that make up the placenta and have the same genetic make-up as the fetus.",
"    </p>",
"    <p>",
"     More detailed information about chorionic villus sampling is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"      \"Chorionic villus sampling: Risks, complications, and techniques\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHY IS CVS DONE?",
"     </span>",
"    </p>",
"    <p>",
"     CVS can test for a variety of genetic conditions, such as Down syndrome, Tay Sachs disease, and cystic fibrosis. It is generally performed during the first trimester of pregnancy, at 10 to 12 weeks, and the results are available within a few days.",
"    </p>",
"    <p>",
"     Amniocentesis can provide similar information, but it can only be done later in pregnancy (typically at 15 to 17 weeks). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"      \"Patient information: Amniocentesis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Your healthcare provider may recommend CVS if:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You have a family history of a genetic disorder, such as fragile X, Tay Sachs disease, or cystic fibrosis. Having a family history increases the chances of inheriting the condition.",
"      </li>",
"      <li>",
"       Prenatal testing (blood tests or ultrasound) shows that your fetus is at increased risk of having a genetic disorder.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      CVS or amniocentesis?",
"     </span>",
"     &nbsp;&mdash;&nbsp;CVS provides results as soon as possible in the first trimester. However, the procedure has a slightly higher risk of miscarriage compared to amniocentesis.",
"    </p>",
"    <p>",
"     You may want to know if your fetus has a genetic disorder early in your pregnancy for several reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Your pregnancy may still be relatively private, not known by family, friends, and acquaintances.",
"      </li>",
"      <li>",
"       If you would consider terminating your pregnancy based on the results of testing, pregnancy termination is somewhat safer early in pregnancy. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=see_link\">",
"        \"Patient information: Abortion (pregnancy termination) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CHORIONIC VILLUS SAMPLING PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     There are two ways to perform CVS: through the cervix (called transcervical) and through the abdomen (transabdominal). The choice is based largely on where the placenta is attached to the uterus. With both methods, the procedure is performed while having an ultrasound.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Transcervical CVS",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the transcervical CVS technique, the physician inserts a small tube through the cervix into the placenta. This is done while ultrasound guides the physician (",
"     <a class=\"graphic graphic_figure graphicRef66814 \" href=\"UTD.htm?26/10/26788\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Transabdominal CVS",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the transabdominal CVS technique, the physician inserts a needle through the abdomen into the placenta. This is also done with ultrasound, to guide the physician (",
"     <a class=\"graphic graphic_figure graphicRef54932 \" href=\"UTD.htm?23/51/24372\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The physician can usually obtain enough placental tissue the first time he or she inserts the needle or tube into the placenta. However, if there is not enough tissue, the physician may need to try again.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      CHORIONIC VILLUS SAMPLING COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     The most serious complication of CVS is miscarriage. CVS does not increase the risk of the fetus dying later in the pregnancy or after birth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Miscarriage",
"     </span>",
"     &nbsp;&mdash;&nbsp;Miscarriage can happen in any pregnancy. However, the risk of miscarriage is nearly 3 percent higher in women who have CVS compared to those who choose amniocentesis for prenatal diagnosis. Most of the risk is confined to transcervical amniocentesis, which carries a 3.5 percent greater risk of fetal loss than amniocentesis. Transabdominal CVS appears to carry a fetal loss rate similar to that of amniocentesis, with a pregnancy loss rate of 0.7 percent within 14 days and of 1.3 percent within 30 days [",
"     <a class=\"abstract\" href=\"UTD.htm?2/7/2161/abstract/1\">",
"      1",
"     </a>",
"     ]. Amniocentesis can also cause miscarriage, although the risk is lower than with CVS.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is normal to have some vaginal spotting after CVS. If you have heavier bleeding (eg, like a menstrual period), call your healthcare provider.",
"    </p>",
"    <p>",
"     CVS can cause small amounts of fetal blood to be released into your bloodstream. This can potentially cause complications in future pregnancies, especially if you have an Rh negative blood type (eg, O negative). If you have an Rh negative blood type, you will be given Rhogam (Rh(D) immune globulin) after the procedure to prevent this complication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Repeat testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women who have a CVS will need a repeat CVS or amniocentesis. This can happen if the results of your first test are unclear, if the cells do not grow in the laboratory, or if there was not enough tissue collected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287526794\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5510165\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=see_link\">",
"      Patient information: Chorionic villus sampling (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/50/11043?source=see_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=see_link\">",
"      Patient information: Amniocentesis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=see_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/59/4019?source=see_link\">",
"      Patient information: Pregnancy in Rh-negative women (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5510203\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"      Patient information: Amniocentesis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=see_link\">",
"      Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=see_link\">",
"      Basic principles of genetic counseling for the obstetrical provider",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"      Fetal blood sampling",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       March of Dimes",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.marchofdimes.com/\">",
"      www.marchofdimes.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/7/2161/abstract/2-7\">",
"      2-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/7/2161?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2161/abstract/1\">",
"      Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2161/abstract/2\">",
"      Medical Research Council European trial of chorion villus sampling. MRC working party on the evaluation pf chorion villus sampling. Lancet 1991; 337:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2161/abstract/3\">",
"      Lippman A, Tomkins DJ, Shime J, Hamerton JL. Canadian multicentre randomized clinical trial of chorion villus sampling and amniocentesis. Final report. Prenat Diagn 1992; 12:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2161/abstract/4\">",
"      Smidt-Jensen S, Permin M, Philip J, et al. Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. Lancet 1992; 340:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2161/abstract/5\">",
"      Hahnemann JM, Vejerslev LO. Accuracy of cytogenetic findings on chorionic villus sampling (CVS)--diagnostic consequences of CVS mosaicism and non-mosaic discrepancy in centres contributing to EUCROMIC 1986-1992. Prenat Diagn 1997; 17:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2161/abstract/6\">",
"      Jackson LG, Zachary JM, Fowler SE, et al. A randomized comparison of transcervical and transabdominal chorionic-villus sampling. The U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group. N Engl J Med 1992; 327:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2161/abstract/7\">",
"      Cederholm M, Haglund B, Axelsson O. Infant morbidity following amniocentesis and chorionic villus sampling for prenatal karyotyping. BJOG 2005; 112:394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_7_2161=[""].join("\n");
var outline_f2_7_2161=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHY IS CVS DONE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CHORIONIC VILLUS SAMPLING PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           CHORIONIC VILLUS SAMPLING COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/10/26788\" title=\"figure 1\">",
"           Transcervical CVS PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/51/24372\" title=\"figure 2\">",
"           Transabdominal CVS PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_7_2162="Bullae caused by Fusarium spp";
var content_f2_7_2162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullae caused by Fusarium spp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1Y4PzuyRxAcuxwPzNcpqvxL8I6EZFudUW7lVv9XajzDx2z0r5Z13xVreuSs+p6nc3BJ+6XIX8AOBWPyenAPpXfLEv7I1SXU951r9oGZY3g8P6PDHknE9024kfQV55rXxO8WawjR3GrTRRMcmK3/dKPyri9mD1zS4Iweua5pTctzaNO3QlluZpnJldnb1Ykmo8nPPPtSrk5xgEe1SAArnHNQ2aqncYhJ708KzHHFORDuwF5qUR4PzcHt9anmN40rEQjLH6VLFCW4GcjtU0UbYz82OnNXI48KCFO4d/WocjeFJdSskO7gja3TFW0gxhSMZ4561atrYtkgbjjP0qeG2Pmqr5EjHH0Pao5tDrjSKKQEPiUsfQetSyx7QFbktyp7VbMTx3JhlZsjkYq3e4dYlwNyqetIvlM6wjVLtS8BePHIzW7dXH7vFrbqgXpn1qjYht3mE/Mp2gHuK1byQSNGWZcAY5xS5E3dmsXaLSM/f5kcfmcn7uAO9SoEU7VLBgeSelDGM4IXCg89zThJ5ioM42ng45NU3YLFiKJNqu25SDj0Bq1JIMJulJLKepxj8apO20/OXOcn29qe5VSACxIGcjoPwqW7miVi0yh40dUZGx0znJ/Go2ZlZiGZj02jgc1WN8NgDA7vUetU5rkyuVQs0o5PpQJ7mvNdYdkkyzhQuFGQahilnMhEaEdwMZzVW0dl5kYyMew/xqw926fKx2ADgKckmpbGkWjNIrKhcp3YCla5D8xYQHhWfjGPaqDyqMMw8st83Jyd1VLm6UhgWcqR94evoKRd0jUubxxGCfmDHB/wA+lV/OJK92OPlXoR9azTI5RAzMqqOGzxUb3Q42DCg9c/epWE5mg9wZZMb9gXoi9agu7jHOQoAwVU8mqK3OCe+B0zVOS6KHgAn1xyPpVKJEqqsWZ7jdGpICKOiiqM1w3TOCDxzUDzOznnPeoJJsj72TWiicVSqWPNzkk4bPJ9aikm+T7xquzk5qBpM9a05dTllVJXfI6Et2IqJmH9cGmNITjLcD2pN2W6cVpGJi53HM3y4POe/ekJwOT9KQuCKb0PI5pmfMPJwo6UwtyDikwxGKD0FNRJcgYk9BTfm5pxzjg0sETSN7d6drEavYbGCThVBPuasxw7SSxJNWIoAo4XnGauQWrMwYjC+pqG7G9Og2VkhJAx/FV9IcAcd+cd6sRQgHOMkdBV8QeSiENjucc1jKZ6NDD23KdvaHaBjrzVuOLykAc4yc4HpUyYUcjJJ4LdTTn8tVBwGbPc96zudkYKJVKR8MeCw+6eKlj3Kq5jCIfT+dOMBlkUgEc49hV3yv3WDhueQBjP4Ur2Ha5WKqZQgAX1b1qW2RFZvnJUdsVOF3IMIQgGQoHSrEceCMYC4+72pN3Go2FijAhHmr1Bzmnou47chVHIx0H5UoCMf3Y3Keq4q7ZW7STKdpQdeB1FQ2bJXPFAPmpxHrxT2AHzDB49KfsH8QrvufMRpkaDOSakVM9O1OKDgL0PWrKQrkbhgdKjmNo0ivHExY/LjNTLF8uOeOtWI7fDZx8o75q2LctImyJmHc1PMbxo9SmkZ3Bcg/SrcVmdxJHX1q5FaBZcFMOBzu4NXxax7OVIY88GpcjohSuZ9vZ/MwbJ7jFWRZCNEZ249OpzWhBsB+ZMgcYHrUbqsTCVQdx6E9vwqLmyppCw25YLuGwEfQ05UIciNgvH3mp6y73Mjc5HJJpiptGAQVxxz3oNLdh86B1TcoD8DevNNB/eOXT7uRxxmnr5QA3bSxH3c9DTXkIiYL8mcZz1oWgcoxkWJEYDBJyB1/OkZ1aRX2AgA4HpSTPvHlkjeO4qDYoJIyPoc1Vyetidpd5UuCqYzgdfpRbyyFiqphtvBPGKjcpFnZJukznPXFCbpQcsR7+tSUWlYbMO+8hevakluBviAAAVcECqu7y3KABix602Rmac7se5HTFIu4+Rx5jYBTngnvSeYIX/eYYsOijGaaNpcFckKOCaglKNyRuOeQD0NMzehdF0xjB8vCKeIxwKJZZJGYqVTPPFZN7dvbqNsTfNxgd6cLh5oUZxtx69qfKSqnQtPMxGB17MfWowxLbHK56gL0FQeYwb52YjsKgllAY9mHboKOUUplhpSCRluOg7VXaVTw27g54qBpWIwMDPcVC0m0EZye5qlExnVLEs2fu4GarSTHPHbuajZ8YzUJOT1OKfKc0qrZK8mcZ4z3qFmAHA4oc/Lgc4FRg8c81qkYSncRWJXPOKTjFKxJ45pFA6E4NXZGTYh6cdKQnjNPUdaTbk8HBFNIm7G4pNnTipQoA5IprSKPu8+9VYlsCpP3Tx60gXsetLGryYCghSav29ng47+tS3YuEHIqx25YjmtS3sGEIk+VULbck1Zht8D5RkgdcVILORlaUj5Rx9T7Cs3M66eHsiCIckEDnmtGCBWiU/xDvjFMt4gjMWQk+pHAq2j4i6A4HOaybudlOCQqw4Tdt9vrQ04z5fG48H2FMeXLDLHjtRBAZHPmKSx/Ws7HQn2LCf6sEKTnio2szcmJo5jEynPHOfYjpViONSqglsr146VchiZWQIMZXGelS3Y0UL7hax4ysiknGcLz/wB9VdXYCJCAM4C57fhUwtkgyGDFWXGeg/OiOEcEEDaRjnJNQ2aJWKkg2ZAKqrdQO/NTxWzF32bcHADZ6VrJpXmA5ixknj/aHP8AWrsFgLaIBkLFiQ/PO4dKlyGkUIdOVZFOJBvGQe1aiQRoMFsFScHHbFCTlhj5tqjAPfH/AOuo40LMxdC0rBh8x+7is7tmh4EsYCZ3Cp0hdD2ZSRU8NsWGHTAFXIbYMpZWYgDpjpXot3PAjArJbnghMEH04q5b2wYgODvzxxxVq1gR4WG35uqtmr0EfmBCVXd0JHrUXOqMEVTaCNcSbQQc9KtKhVFdAYww7nPNP2fvT5rb1HO30qMhVO1BlupGeBSaNbIuQw+ZgStuZuCc9Ka37g+UxBKjO71qmJQ3CKRIOabNcs2Oct91c9qViuZLYumYCQlVOO/H60iMJBIhzllypIzg+lUg4Zd+7BHDD+VNjmlQ5iyAAScd6LBzFh3MZKShce3YUSTx4SIEEdsU6+hWEWwMyv5i7yo7ZquseFzhFHHNIOpM7gRhhhZM4JxkYqORiTtbOW4LZ70FQsijce/HapHGYxgYY9KCrDGi+VVDYA6kdTQzeSmAMt6U0sc/KQSD1I7Usn3cqdyjoemKQ9BkRKcsQpPPSnKwdsI2D059KjO8NhnU8daBhcYP0GKYEm7GTkAngHd+lMEiKAF3LyaVmjwM7dvNVnKiMFDwe3pRYlysTFtzKAPkJ7nrUBdEJLAbQeKjZvm4ycHA9Kjkzklm+Xvx3qkjKUh0l1vYsPu+1RGTKY6E9yagfrhWAx1INQEr5nLdOlXY55VGmWQ+V5JBHeoGYFuW4Hao/MB6H8KYSQAee9OxnKoPZt3GeKi3HHpTQwAG7PHekZwTnqKpLUylMVmHTJpvakJ4zilHpnOaqxk5CNgrgnFNAOeKftBHNPjjyPTNUkQ2R7d3WnCJsj0FOZ4owATlqgkndxgHAp2JbJXZEHJH0qBptx+TAFNVHc5VWIH5VZgs3f7y4xT2RKTk9CCGJ53AUc981oW2mN1fJ+la2l6U8sgjgUPIFJx61qx2iKpVvlx1B4OaynOx2UsLzfEYVraktgLx0A9a1obNVG44yCBg0m5Y2OwDceBgVNEHfDZ4XqT/ADrKUmdtOkloTzWsm8AKoA9+tTRwr5RztyOQzHoO/HrTnkdMYcNgYyRnNUbi4EYLgEufu57H1rKzZu0oobdThZGBxtz0FUoQ0r4UkdcmolimuJSxJBLc810djp8ccedwDqcMBzmrdooiCc3qVbawGzJBLH8c1pWluSqqEYyA4Oeg96spGDJEY0yAcgf0NWYop3O5I9vP3RWDmdsKaSK62bDczMA6jjJ6nPStEyiW2Eaou5ByOuatRaXO8m0F8EZBz0PtVzS9NFteKkshLurHGB26VnKZpGJQtNJubxRvY7EydueMe1a1nbQxSzRJEpyBn6+tXp5pCytBD+6IILdAD3FUpGMUpYr5bcA5649aV7go2FGPtHzEqV4H+19aHvA8KtAhYhs72UryOoOartcNLJvZQ5Ujeo4yPX+VUpJ/M3LvVznOOeOtCiU2Xd6eanmMWjZsEEY6ml8xVlDBizkb9p6+lVBIvLLgsMEc5wc1dskG7DDfJl1Jzzt7U2rCPKTC+3BUKrY57ipRAIzHGhzG4yu7ikEu0eVg7duOf50gnymWwAp+UGu+zPJulsh7fKwjTlT8xx1p7MsWDlQT1ABOKrF2UHcRlvTilALvv3ouRgcd6Q4t9ibzW3KxfLL0A4BFNNzvlBL7WHJ+Xp7VWIMili3OOQRjFLEAUIIHqSc9KQ7j5GCymSVQC3Pyn9aXcu7B5PQccYpnylUcJkA/KD61JHII8lV3En73pUlpA+5SeTgkDA9KcQqZJJBxgj39aMlsGZl3L0I6kU0uH+fPt0pNlpEsiZVWJ5wOcc0wSJIxjHcdDxQJR5T7V3HoDUEdyFcBlVdx6kZpINLlgOVjYFlPY45xTCzja78gjg+lIctl1IwR0x1pH/1JCZ259OtFguKZA4CEqAOhzjNMLFVOfmRjwP51Gx2JjYOR3HNNJLL82flHGOAPanYnmFjO0HOSo6EjmmmTg8E+pPf6UNhSfmIzyQfWq7uD84yc8Y7U+UiU7EhOY25PHTHfmiTC7ckYHp3qAtj5cd/4TTHwUwex9adjNzLTSgj5Sqj8zVV22PkcjsSeaYZAAQMcVCzZBIaqUTKVQezYBK9KrkgdwKCeu0ZzTGY45xn6VdjnlIcWB+6BTWZt2M03JJ6n8Kbnnk81VjNyFYk98DvS44GOnalAz1U/WpFUcbsCmkK5HjJ4p6pwDjGOpoZgeEXdTWilk+8cL6VWiIeojypGePmNQvM79e/YVYSz5PJOKtRWg7IPXNK41SkzOit5JM/IfrVuHTzty/UenSt2DTWXBbB3DOAe1WktkRh90+iipczphherM62sC2mll24jlxtH3jkdfwq3BYnPzOv09a17L7OtheRNETM2GSRTjbjqv0NVd6plWJx2+lRObdrHXSoKOpZsk+yyjYSjL91gfm6dqnuF+zzPDcRskg5ww5APrVO38wvG+4QLuAEhOSpHepdQvGub6SeKSSZzhWlm5LdvyrPl0uzdNJ6Iz5lPmuRhR1FWrVfLgBcYLEn3NKltI4LNyBwfb6Vch0+WRtxyiDrxUtrqVGEm7oplt0eQMHp7moZLYykjk4PArootL2IGVdz44zTorEgAsn7zPPPSs/aJbG3sbrUwrS2LOrAfd7dMVt2MSlSpI3A9uhq9FYQjEm4px0I7+lXbWOFfm2rtGEaM9veolK5rGmkhLW0ycR/ebt1z6VrwWqRqzPkA4Me3+8OozVeArAAF3G4iO7b/ALPpUzzASHaNkLDJyfu5rFtmli5PM2SsChGUeYMfqKZMjDZMJELhdwDdx6VBcXW2zWYAMQ20lvSqMtwkgIRt64ypI6A9qOW4LQvrdlsx45Xk88E+wrNubkzvmUEOPlCemKSVs4LHaQMZPr71XdSswbPzNjBA6e9XFEt2DduWVlbaznpnkjNLbIoQNyS5GBTGbadzEg9MD604IY5cb22/w55AwKslMdCm51SR+NxbKjuO1XociIO2chAwAOO3T61CuA+TywGc9AvFWbddzKxPDRkgeuMVLKR8+nUr7Kk3DOAMc1NHq98FxuQr7r1qHyflPQimLEwI6cV6HMj5pRmtmWv7XuimCkeB0qdNbmAGYE49CaobOcA0LGRw4+nvS0GpVF1NAa2xfc9spz15PNSf20MELAQrdRurLVAMjFLsPqBRZFe0q9zUOuKAB5LD2zxQNbiBP7p8kYwD2rK8sHGRQ8bFO2R1pcsWN16qNlNbhCgiKTI4yfSnf27EE2+U/esMpkgDg0wrjp/KnyRD6zVN463Du4t3C+mahl1WJ0IEDj8elZW3gYINOiAJ9PrRypB7eo+pq/2xuh2rCQRxkHmkTWHRShh49WOaqLCXHyke4FSx26jcDjI75qdDVSqvZjm1LqTEckYzupI9QZV2+WW+p/WgRYXcOc9BThalxjj0zSvEdqvcZ9vdiC6H8+tNN22cBcL6ZqZ7UL8uFLD070q2wbauOSOtPmRPs6nVlbzyeNpx3570kkzNxs696vrZnZkDIHXH60fYlHOOvSnzIPZTZnmQjqg9sUnzEHKjNXvsqgnqMH0pRb4wR3/WmpIj2M+pnYY4AJFIIm5GPfk1pG3G7GOTzQ1u3HHHrmnzoXsJFBYzjJwKFi6k9avi256ZFO+zNnKgfjRzof1dlARnIxzTzHyMbferptjjginC34GRj8KOdB7F9ikseegx7VJGFbhmAq19lIJA596cLRlUnA45xS50WqL7ECn+HAyfSrEJKkgqrH86etqe3JPXFWorIqPm49aOZGkaUrjQ5IyRirEbfMDGAoPpU8WnGVlLHA9qux6aQnzKck9PWsnNHVGlLoUIXkMmwHAYEZpnlSs/OCrcZrVGmtnlSp/h9a2rHTIwhPzEJggEdamVVR1RrHDylucrDYTbwQpLDv6VtWNlGcEjO7g+tdKmnRyLkJgtweOlXbDSDsMnybQMBQOSfWueVY6oUFHUxxpiRujhVwBjk1fi0/LFQimHO0YPOfWtODTxPC7xqhwCPb6/WohAibiHUgL1APX3rJyua2SHxWcTMUk2KMZHrmqk6PEwYAKrKVYsuCR7Cr8ccbMcxqc8jb646UX0YlljTdvVASB7EZqUFuxjhYnd9wZQRuJToBUc21WUw/vY3OD2LGtG7iXZG25Fcdh3xVEofKKYBB9P8a0RJLHOJ5SkIIAHz+oPpVdpVRSpURxj+JzkGkiKyvIZY237cBU4OB60+O0MlrGrfNgHgfNV2Qik7FIyjNkN8wAPQ1YWNzD5Iwq9evOKtfZ4njUnZ8p27R/OmmNY5HVeXJzz2/8ArUwKIBOVxvyACOSG96VIypOXCoTheuTin4VJCGUkrzwetPaRZp0WRiXiUqqnuB7j0zV2sZ3GzqpkBCkg9QR+dKYVL7o2PbIzwBSfOD5qM2AxA29himxcO7KCEB53d6QXRKwdwruQWL4C7u2O9adruaGJygUrJtOOMADr9KhtysZEYUYZiM456cH61q6bEZYjHtXe8QfcfQHH86VgufOfktGFPG1h0zS+VmMEKcg/nVkleFdeenI/lQYtgYBjt7Cug8lRKsiAcLgH3FRbMP8AeGKtOuSdo5z3qOZMZwOc+vFNEOBGQwUnacdiaaquWA656DFW7hlxHGhPyrhj6mogSpAViB1JqyWkiOQsCEHXOORUjRgZTv3IpnnYYkkMD3pwkGDhc5o1FoNZADzkr9KQpvOAPpmrDQ74RNE6uv8AEM8jFOjWMsoXIDHB4ovYainsV44d77GHQdqkWz3kAEE9easywfMxRW+9jdntViG1IYBMgjv3x3pc9jSNBsghhYEgjYR2xgVftrVZIsyEAlsAf409YmYFj82OBn0rQt4lwpKFWReFP8X0/wDr1jKR106XKZCQKCwZcLnHXvVmO2+f5toUDORzmrrrhVLAkAAbTwTUkUCupkBwR2I+7U8xv7NGfJbxFRIpI6Agj86lFmTuRVII6e9X4oAzbnG5lblE549asvEyKrqrZyGGV5bHbNHMUqaMhbbzFESjgnLZ9R71MLOTAQIuXbC5Nbd3ao9xIkT7bJx5ibhgjI6Z+tQ/ZDDGkkmX47D170cwlBGXPp7RzE4zkdj96oRYHax7L/F14reiaPyY9iufLyyMR3zVqKxE8U2SPnTc20cKf6UXBwRyv2PgMdwAGcEc08WiBGyD6g11ZshOYjsbdEu1h3ZvSqUsCB1SVFjB+Vd7YJPoPWlzMFBGGLJWQbRnceAKRrUquMbs98V0DWzn93GiqhYAEU/7KFjbcFwGwxJ6GnzMfskc6lq7PtkA64xjpVkaflA+4+X3AXqa0FjlmmBaMshOPTPvU/2Y5Zefl6nPX6UnLUaomU1kNiiJfmJ6saVLTnLAEA5BPpWr9nB5kIIzwCOQff1q1FCrDI+Q+h5pcxSpIxLa0jeR94BY9D0FWILPJVXJAJxgd61vs4MylmJibgKP8+tWbeA7ypXbu6AilzF+zSI9MskeI5j2xgnDitBLHdAodQGGcnv7VNaELEWkXGDjYD6dqsShXcMuV3H5gRwB2/WsXJ3NIx0M0WmZotoQkdSTgY960YLcLBvyudpwD0PNSWsEcuFkUlidxJ4GKktmjZGUoXCnC5qOYtKxetsFMnC7jleOmPSriLG/7yFtsRYgjP8AFWUjHcA8rHB6EdF9qtiWI29zAULPu8xXPGKkb0HzwlcTJuSLo/GApz1xUEbjbJtClWO38fX8qtS3RnWOP5M7e+c5ArMYRqz7QQSctnjimtRMtBEQSBGJRvlypzg/Sq9wGR96fOY+JBxkg09JQGIVF3ryuOd3rVO6ukdy6qdwAOdverUSG7FeWYLGyxldkmQSfaqhuDEE8tiYiORgCpZTE7oZtreYMZxyDj9KpCDZAzONxIxk9hWqiQ2Pa4/enJJdwWLNxn2pguDGwjUFUHHHoe1MgkVrbDMpbO0Ieo9DSqFkiO35pOTuIxWljPmB55AgODsfg7O1QPLLHt2lcNwOeRVhGRrbyZowqcZIPNCbQzgZZD8pB5xRYXMV4J5VMpyQ6rjdUkG4YKsQckMAe+P/AK9NVFQGJhuVuhqaxx5jM67Qf1qmIltCq28aM0jYUhvY1alsnVIVKMyyg7OeTx/9aoRLBHFI8zLGi48xnOF5OOT2HI5rotJ00QoWkZnYFUEAILrJu5wP4eOhqqdPmZnUqqBTso7YlWYuH8vcQwye3NaFsjW6BQcAFwfoecVZS0Iu3YwiR9hQ9mU+g9aksoI5AIonkd9m9gVxtOMH61nUXKyoT5kfN0ysNp4BPOalNvl1Lcg9u2atfZ2Ie3xuxyGHJGKR7eWBEGwOrAdDyPrW+5xWa3KE0SI+MkH2qrNl+QRx0NaE0Yfcd3Pv0FZ7kEHav4VcYM5qlRRdiu7sPvVC7Me+atGNnGXVuDgkDgVHLECfkU81qoaHHUqN6FQ5GMU4MwPJq2kJHG0/lTJrcJyckmnyka7jRIUXCk4PUVoWGZE2598GsnAOcLnHvVi0maGTOeMYx61Ljc1p1XF6m1FcZkUDAZeADzVoN+/ZGLLIMfKR3rHt2O8jlT9a24YZ54kl8pnP8UnUrjvWE42PSoVHI2JNOQ20LwzhuzqBjP1NSrbTRSGWORUWMfdHOSe2T6UaVd28c0yPH58cibAV67uxA71NCZrWzwSXidt+DyQawkehAjjj86+AlO0upK54zikQOHaDOLdyCWIyc+lWViDuGO6NlwQcbhjr+FPk3TkqpKoX3K6jqf8A69SacpXshDGZRkoDhs/xf7oqdsrcKhckBcKM/wCeaiNuv2lITjd046A+9PwpdlYnzSCSVGen+NDdxpWRaijlbzncB4wmOvQZ4NNdC1uGQK8chw/JxGfSpLG8hWMRSKBGM5THX8frVm0kWO+jijTzYXYOdowQRyVPrTRL01IUtjBD5e1d3QlOcN/9erUL7IRK5UbVyVXq+ePpVa9kit9RuPLYyLMxMe/qw7H6ip8qlpBAmwhySjP0AbkfnRZgaVuI1ZUl+QzRlOD9xx0Y/WqywsFdJlSRIl53jLZP8an2psskJhMiABUIV1z9w45B9fWlMhkjgdWzjoMdyOF/EVSJaREyLHKQCWifKsMdD2IqO4h35jAG5gCfcf4+tXSiKjIwAkH8APft+VRR7JdwZv3uSRgfnUPctMrRR7HVXf5GGVxzimmJ2clSdo53NwSKuOiKGRBHgr09MVHIqmPLLuyeCG4zjpikWiJIVkchZCNnIB6moiW3bACRxuO3kGnw52rGVOV5GOp+pp5by4zvbD42qPegbC3RICqsxIx95qswuPm3lm3t1HoO4qDYCYw+5o/vEY5H+TV23TAuWWMrkgH0Uen40luDWgQQkPKVJ3hs7elWpXSPADk8fd96jRFuJEyvAbDPnH5069Wa2ilX91kkKnOc8+tS431KixY5mMZJb5FOdvXj0p0boVYxAo24Ywe//wBeq1vEkasEfp19DU9tu2lCBgEHfjt0xUtaFOVnqWYgN7MFLFuV54BJqSeaWKVZfKygxkA9veoEWSJjuIC9doPrVJnMknlvIIlZghbqBz1qYxuxt2L6XiNcbTNIWY5AQjipNXXc4+aRlOOT6+/vWSFX7QwWFgIzjdg4BHetGOJmT5fmGd5543f/AF6bSiybkUbFELBhhTldvU1Wmfy8vuOzH5n0+lSvMZFKRjpk4xjFV1aNsuzcnj1wK0RmyNm3S+UgVh1we2f8KY4DysjmRSCAT/DUspS4iMnmsEYkZC4PFQzsrJti3Mx7Z5x61oiGyGJBGrAxBSWxuPOaVoj5jsjhUPBWpZriFI1MaMJE4bP86hivAQ6nOSCV3CqaMySZNiAAPtYZJ64o2JGxOAxHTnv61ArSKqxuwG4enahg0cbMFzGrZB7/AEp2GOkKry5BDfdGM4/Gp2MQfzUZjtyBt6DjrUUgOwBQu09MetaOiQq8my6jd4F+YxxsASPr25p6dRehO8ECaRKbuFZobnh4sggj/wCuaveHLkzahHEquI3O1yoxtx/dFVPJkmidpCHEY2AHGQAePrxS2/m2QS4i3eYkokU46+oq1VSsjH2N031OmidzO0jIzbQNoxjgH+daCQRxWEsqFhKkgTYewzyc/jWPpt1JP5ckkmY97QbGO0gkZyfSrcUrSLlXLF4hkk9SCc/yqKjTTEou1keJXFq0kINuhjk4+UHr65qxPDDysK7T8qtjscVdt40YbXBwpA3DGabpFsly728bASSu4j3N0AHGa1iZy0Zzp00zSXKICwU8Ec5qqNFeMxvL8iZCtJ1ArrJLYWt0sEbBfLGJOucg96i1GBbixmkgWTaZAVjPA3Y7V1U1Y4a1JS16mIulSxPcogWaEnBPRWHrW5pHglb+AvbOjXmWLxZwFUU22luBatbSMiLJmaVz14HAz9e1b+naomnLPfxuRBJAsIyu3cQPnx/jXfTUWjz6l0cVqOmeTZzkRlURxGrkdW7iuaETAurKAT0B5Nd/quopf223ZHbQY3LEOpPYn3ridUUWwfOSzH5SfSsa0NboIt9TGdNr8cqeuKa8YzkdBUwGeTx601gN2WB2/WuZod7lq0UNKNowM/rXTWU0kUGA5QuCpKnjHpXM2u7zAV55z9K24JWC4Jwuc4PrXPUR6uEtY19OzZ3CvEFDq2QSMhTVyESC7jKy7Ys5csM4z/jWUpfzQTtCE5JbvWpECEWRVAdVAIPbnjFcrPUhYnDtA7KXdGAIf1YY6VLbsGRRbKQjDaiHqvqaRpULbnMhB+bpkgipdPnS2dpArlmBZeM5HT8Kjoapa3EdAv7iMhZHOAX6H8ajlCxRRIBhmG5ATk5zj86IJUMDSMS0xIEeR0Ocmi8USXDuqFGVgQccZ9aYyW1jZ7sLIykyHChvX0NTxPgMw/4+FOYyvG1hwfrUMzTQwnc4ZCc8DpmhJfMldmUqT0H8QB701uZyV9AW4tnnLT4Mqp5iKBzkH73pirojFxGyMAsa/OJB23c4/CsOTZA2VKt5bFduc4z2rQt1nuJLRF2qVwpJ4Un+Hd7VTZPLy6F+3K3Doqxne4OQRw+M8/XijyxG5hYtghcbf4N3Q/gakLyofM3BI0bDKRjyz3J9qkuo/KljZTtnY7o8nAcHvTVxWIL2EJfPuIJ/jbvux/Kom8xwACQqk78DAUe596cySySPNOuWUhZNzZ4zxge1OYvEro7AlyrFO3HapauUnpYciBMgjCuOW6nI6ULhoXjSXIYEOduTz6e9SOCx8wFki2r16Dnt71JDcBrgOmQDwQF69s5pJa2KcrIpSQboQA20KArEdWx2oWEBy7j5nGAG5xV0KS+2LBZAVck4Geh/Gqd+584INoPGSeDgGnsCdxFYpIuZGEeME47+lXdNKS21wryZCMGx3Oe1RSq7bMYRCeh5yKist0HmgEBSpUjHv1qZJMu5ejEwmEjZjiYkJEvcZxn3qbUFYXrQBwpQA7tuSRjt9aWEyosUtxMQiqSiqAOPf3NPe0kk2yuF8xhuwDzg9BVKK2JbsZA3wKVjVyAcru9/apLHftQMGyeufX3q08WT84dHHRmPX2psSGMBixdycjP15yKh9irk1r5m9XKnaGw2TxVXVJEjuXyoLcEhR8uO341suscciAIQ8rDEa8j6VQ1OPJZm2sVYgsOT+XapjEHK5Q+0TIB5e9mYc4PXNOt7wQhmhL72JzznbVUM251BOfY8CkfET8IeRktxzVWVhJl6aSRgXRgUbnIH55qEyFjgBWJ4Zh6e/pVyyhjazZQ6KR0VjyR6j1NVXjKFflAHRst1pJFEO2MlwQz+YMAZ6H1qpI7RjdsySO3rV6VACpVQFyec/dz2qIoA7YTeuecjA/CrRDKUaNysnJxu5P8AOmI53fN905A9PpWpNDI4Cqiq2QMHg4rOe2MTFZG2ruIXPrV3M7F+DEjDoSF4wOQaIwwOCATg5yf1xQY3iRCGYsvzhj6Gn70DBhESTkEt34obBK4y3TdNznBHHH3a2rWFVRGBbdKDuPAGFqjZRhgGV9rcCtBFdZI95BB3gAdh61ncqwsaNHJK6HKq3I9jUjZ8keYMrIjDAJOMUzKJM5kHMy8M3cg1fjVAGEgBRDu4P+eMVLuFrFW3/c7mZUkCOkxDZxjFbOnnfJCFUBMkAN1wfT86jNtH5hCsm14uRjIyKkgiJKSD5mA4xwfwqnK6sS0eOWdvc+cIpWASRiyhj93mtCGJLYb926WUlGIH3AO4qtAu66ZuSJPljUnIB9hTrSdXuWtDIxijOWxjJPQKfx5rrSZxuSLxAe0VYpmaZSURmThx6Z/xqK7mFjZFUaG4klbb8uR5Xv8AzHFU7idOILp9rRnaiqOZT6n0qxO+8GFPLYxqxK5xjjnJP8vWtIysZyjcq3MiQSwmVAzBwzAfdLAcD3+tULu9mupPNukCgDasf8A7gYrQ/dQJDcNJJJ5RGFIyWz3IrISOdrl3crKGywRjtxnuK3hWtoclWldlDULyS7ueW+c4MjEYA9hWRcMZBu3Fh0Ga1JrZf3kUqtCrDhiec+/sayiThQPlx0wO1U53OOUGiMnBYYB6YzSEYGMc9zT44iQS4IPUAirlhYzXS4UFkDYJzyfwrOTKhDm0sLpcTGRWYd+B6ntW00augZ1ZDE3zEDjPp9ahmtzZOclWkz8hHAP+7/jUlxelUigjfen32OMbmrCabPSpWp6Muw75HwE+YKGIOMAD+tSh5JHLsu1T09vrUBZGtEcPxjnb7dAasaXcpFdpn52IJ254HHLfWuZpo74TSL9ibWQ+aXcSSEIQ3CgjoKmhkk8uSSKRXUfLk8EYPJHt/OqUNvC4kwhdV/DPtU0DfuZJETEQI69F7VNjRSLqRC6lj+aMEhhuc7R06/WmW4KW5ilkC7Qe3Lt2qB3QRpzl0zhccVPCjSxLMNmIhhlzjOe5pWZaZPJbLJYr5rKwcZCZweO/t7UyO7d7vbBDueOPy1d+AUPOPqKzV1JVvpbNYZ2ZF8x5gAEX0Xn1HpV9H3SLMreXMvJ3cgen4YoRN1LYhICLlk8yXBOOg/Op7ZytkSH2/wATYHVTyB+BqnGomidopi0kbEozfwj1pxkllt8Ooy+MFOMAHp+FXYG7GiLuWW2lErqVLDd64PenG6jTbG7722jDfe28/wCFUopAYzJIrKoXLsBkkVJbNHaXjIxJdBtVQmcjHU00hNmj5xMTFGVxGcIduN+f/wBYojURfJJHvYDa7bjkjPX2qrbxN5Ujqp/eH5M9MdBj0POfwq7aXsCwsL0PLIJsK3TKgc5+tOxNywPJKvBlpBCOFP3RnkGrCSIIWjiVNgOZCrZAHbH41TaK3u5JbW2lMKFCzyY4x/CvHepW8qxhgLxiMvldg5GQOhHvxSsF+5G4jitllmcsjEkv1Jbtx/WqPku0sbsG3D5jk4B+tX5I1JDI5eOMAiP+ED0wfes9mbzX3p90bgpPr7+1JxKiy07PFKGztAH8POTSCQM6K43Nn5sjk/4VEciBXkZjnGc+vanReaHkfnaOrDnBxU+RoW7VlluZEdcw7/mHU1oyPHaMFjkOOGAJOQPT61Q0eVFniDsyguCxUZLnPpV3U3Z5rneN2W6BQGDdsj0qorQzm9bEaTJJ5oXLbju+b+R+tRKjJMrbQqhsHd0Ofeo0wqM5ZSwHQ/w//W9KhiuEedUVjuABVm6D1Jz1qVHWw7s3WkTz1YnBA5ccnFUtUwLQAqULYYAjDn2PqO9OtflRhJteAMDKScFgO1UdSvBqVwZGDxqOI13HKgVcI2V2RJ3dkU/kkwN2W7k8YqcRoqY4U/3gM5BpkG4FVwCu0bs45NE+0BVJAJz2+7USNYMliVknjKHMi9CeuKkkQLJ+8JZWBwNvSmPkyFlmf5R8pA71es8Tq2ZNpxxnnmo2LKjRxHlskMACpGSD7VDJCoBEY3gHKFjj8a02iIi3AqdvOAP0qBy5kKkI20ggrnoR3oTuDKG4rcFGYsc7uBnnvSTJH5quxCr0O8Y6+lNnVS7lVYKTwR/Cahu8yRE7Tu6Lz3rRamUtCSFD5mXZvKxsLk8j0OKt20KzQtKQd4bA3E1n2BfLDa5GwNg+o7frWtYKVd1JKqW+9wcD2qmjNMnslMMUmSWJbb06Zq5GjMittYmNsFUPzMMdKrTNsIEYwmVILHrjrVkXH2fUpHjjVy4yVkHG0jHFZOFmaKV0PvbbzYYNv3Vcjkeo7+9XLa2d9P42kMMH34x/So4XZhln8wAhue+PX8q07H5d8RwhDblBGcA8/lUSY27k9pgLbFgCwwdzDHsRVi9s3XEiMBGPlORjafao7UhFxu/1LlgTwGBrTmYPAQ+SPvAA4JFCMmfPsUgij2lmDBQN2PmJ+n0qCCONIpLeLbgb5vRuD3NUF81bmEDAVcnZnkfWp4RugYrI3OUDYwCPSu29tzl3RLZyw6gPLeby2UEo2Mlj6e1MMsyPA7IpPRU6jPfPofrWWInhn2jA2HP0q9bzbInXdkp/F3FNO4i0+5LNSHYmQ7G6ZwD1qhcxYy4LFOqrjp75oNw0IAQhwOuRyuf51E8p37Y3MbN/G3OfwoE7CSPJcQyRsQ+4A8nlQO9VDHuXciYjK457VdnYTTIzpCGUbX2kgP8ASoY1PzEltxOVUD5QapOxm6akMs1jisZvPiJcgbWY8ovt7mpIDAkbyxZQAAJzyc9v/r0lyyMEXadhPzDu79yfaorthsSOXYuBtQL0X3Pr9KtO7M2uRaF+G3vr2CeWJUkYY356qM4AA7E0anZRxeccPiIBJG7NMegB9hTYdZMVgsELNbxKAVBHzTOOjH0AqleayZ7COI5MUORFEf43P3pG/pW7Stocrn1bK8Ny9vLGXDG3RtrAfxZ61sRywyxIbeMmE8Bz2Poa5yacyQBOQgOU9ye5qeCciNIsnCjAIPf1NYSijalVcXqdOLhYYEQsyTEknnAHoRU13ciIhLSd5AFU+gJ78ViwyW7WpllDMc4wT29KfBtZJpTkRsPmXPAPoK5+U9BVTRktZkikuhISZWBB3ck+gqU3P7pLfcFdMs5J457fWs8XT+VAxcggnae2enT0HrRcO08ifMrIgxj1PrQkWpm4s0e2J8yDCndkhsA9vpVoXsIkDxxBVUbCR/OudjuDsMZYEng9gfap0GZJEwzKpGSOlQ43LUkXGdWZDbkDJwSR2qczCJ2dVUqowBnjdnrWXBKfO2LHz0AHIHvVlZ5o8xx4CBs5boTTsPmNZLlpMxQKsazKVMjdMnr+tWi8dpPsBIneJY3DYOf7zCsKGeS4BcBQVOCCcD6ipCwaUGRy8wXCsR1oA0/ODWjCbZHkDAUcgHvUVxC0liu4BXjQFGHG4Z5P5VGksbr5IUK54D9eP8anuXWURxqzEqSoPbHoP89aYamlYSojNJE8YcxlgHONwxUF8Bcxx3M8jKw+5nhTj39ahRm8otMqiRuMr1UDtimXFzMYxDsBjxjaw4HvRcbXUuRXaQbxe7XGAQingGmXTNcqmUBx8x+bAx7VB9mSZvMWZzHjABXgMPWog0kJUSgGIjYhHUinYnmLg2zPNIDwDwC3YCpRMqSkbyFZSSFOcdOtZz2rwQR3MFzBKzkqYwfmX6itC2EaQvK8bifrggcj0pcpSkWYjEjyMz4YlWAxyBVt7gO7NGF3Nldw+bcPWsyF1F4PIwfNIDAdCDUj/uIGBC7mB8vYaLW0Dd3LCiAyxQgOwIzjGAwHStHR7S0u9btLe4kEcFwxVmCjoQcdffFc5HdtFaIjtlT/AA9WxVp5leFJW82KNAAF24JA5B/OiK11Jm7xsjW8QTrHcrDaNAkNoCmFGS7dyT1NZXlNvtyGO6TIy/BcD2qKO5tPNMkLsRycOM068f7W0U6g7IcIXA4B75980NXdyo2jHlLTYSJt2N6n5l9adHEXTALDGPvYOKjkj+SHnLYIZs5z9avRW4RlZo2zIoUMvIX3NZyjY0iyu4KzquQFzj8alDlWlVVO7OMZxj1ouFP2lkCbyPmweOlVvOYPukz855I71m0aolSRpFUS5ILH5AcBvemTzEsY4+hG7C9celMnk37WXBKkkFew9KlwymIxhccjHfmhITZThwzFflyOOmaf5EWzluW+6AcYx709mjCMZD5QyQpxyKkVN0CSbiUB/iGBVJ2dyJalKGFkLskZjRTuZl5JB/nWjpilHk3R53Aqu4cE9c0ydU+QnzCpBVsDAPpz9KS5jICRgOzBOGLcqe1bWurmFzSMNvNabLuZjNGdqIpySMdz0xmo4la4S2PJYoyED7wI7VFFGzBY2kA3qHUZwT6jirVpB5G9sOfLZZOpPB4NRUY4dyzbIUk8tlI6qdvQZGR+NacMLm2E4L74sH/eFU7gql1E2CFLAMO3PetW2X7Ni3YMYpGwGzgfQVhLcvUtSwgIBkuGQkEDp7Gm6ODdW0uW3BhtCM33cenvWhYNuiaFlHmhSuO3tWdBILacSSRsqgkMVGF+v1pojufN1rareXO15RG33mZzxipr6UB1ghkXZ97ee+O30qgbllAB4ZlwQ1RRLvD7SQ4+6T/Kuyxwc3Yu3s7pIEnh2zZ5O7jmkeURoQAEUjAdDnJ78Gs9XwQsnBzg5OafLMmAqsxAOCcdqLWDmvsybqm0glV+761JbXDFl2xgEnoehqoZi75JIUcCkDgLt+Zie/pTFzEkzq8zOxK45AHahblxyf3h6BSeKby4BYjI7Y7UyWQFtoGEHTjFIGyWSUQMP7/B5PQVVml2qWABLc560+di8e3YWPXJ61DcQp5JdWIf+70rWNjnqSb2Ks0xKAOSX6Z9qYSGYOxyc9u9SGLKABctnPXNNeHJ5wo9q0ucjTuPeV2UYGD/AEqbTxiQDOVAyQe4quFdTgjt61atAfLOcAdcnrUyZpBPmLTOBF5jA7M4VKnjmVlCjCjGcHov/wBeqTEyBVXOPfufSpbt9mFVQuxQGHqaix1Kdi7C8cihYxhBwc9hSnMxVvlRAdoxxms+KXaueVX17mgz4I5x7VPKyvamxa3CIZNiCRgpGH9+4p5usW8aGRQO+wc/nWVG/lgKP9Yex7Gn+b8mwnLGjk7miql1NQ8nakY6DDEd60EKsiiT51xnAPSuWmszIdplZFB3HH8XtWvbyNEmVzuzkClNLoXSqSbaaNiGdYwyoMpnOAOCemM0wSSpguC7dBxzj0qgJ2OxiSrg8Z6fl3qaS7mkXC7PM+7leMCs1Fm/OWbW4hUgFtwTlSO596ka5UOSm9T94nt+FZsgZQkablUHDnOMmrWmx/O0KAuUR5FyeBxz/wDWppXB1LHQG5/cBJQAIwVG77xJ9fU01cP3JQ8epzWWpaSNWb5mAwSTz/8ArqeGZ4irIADncoY8GhxKjNGtNcOlsI0cjHDr0BNULmc3UwkIIGAGOehHGaiLTyTK21UQ87cZ/CmyXcNshAj3yMDnAwM5qlHuyXUTZYt9rHEgdgemOvXuauPeSxgvtURKuNpbPGemazbSdJZF3jcSTkdvp9KmWWFZdrIFQrkqOTgHk/rT32DmsW47ppoY7hgAyMcKBjgcge/GahnukjudjDarFQUA5wf5VFxHp4luAsQct5TZyzjPBx6f4VTkUxnznXORg89fcUr62KTe5sr5O9mdwCMsdy9Pb8aaHnYq0JdjJ8qbxx78VjJchsRNIFU/Me546Vehu2jt3NwxcuwGR94D0HsadhJ3dyS4uVgs1tQSJ1JyDjjHYGr6aiDpsNusQUAZJI5LepNZd0plKSyJlJYyyFQD04P0pzxxWtlDJNIqzNw8Q+YgetFgvZ3Zt2btPHJOJHYR4BDYyfp7VcSQqNgdsE5JzwR6Vz1tcs90zw7vJAA+YbfxrVadJdN/0qa3heEFowvLS1lKFmbxndGm7o/lvuGejD0B71RnySgz1J46YAqobxdieWuN47HJB9CKJbtWcswOWUEFvWpcblKfctyxHyyoYK46elRRTn5AchjwCBVdbkyIzMMEjkdfrSwvHE2IssGIwxHTNOMSHPUtzLjG45x2NJa/PHKj/MNx4JzwPSo7hmjjOwE57k1CsrIsrISdw65xj1pKNwctCWe6JUFD+7V1OMdO35Utk5fcWIUE7DuGTtrO+WQRnLAcq27pjqCTVrTC0s7hgcyLn5T0rVq0TFy1N6HzRqEeFIBYDgYwMfyzXTwW7Ndz20hO6SL5AR95f/11i2uLiAE5X5WibPJyOa0rKUrLZPIpLY2MxOfoa5ps0imkSPZsjQqwOCpG5+gI7Vvoo1HTPKZ1yoG0AYKMOlU9WiCQxTRZKJJuI9u9X9PCpuZVBRuprKWrKlaSv2KGnX+Lx4roeU4wGH07itySCM7wQCpXco7YPtVG80j7WzzRt+/QjBI4YdhT7K4E2InB3KxGB2+tJOxnJqXvI+Q1Vm8xgwyRnBzk/SrFzH5Y2eehUDOMYIPoR61nhnIG0k85696duO7J+8DzzXpPY8tPUtXN1vit0RFTy0Kkgfeyc5PvUaMHJAyQBxUe7qTyKGOGJGQx7UbgpEgyRtIDHsaUSDacDkdicCmMwZR1ph5UgjntQojciUS7kJORg8DFO5Ygs4HrUQyMjOQfWlI8sABlb6UWFzD3Zyx+bIzwB/EKQ7ScEYB6Y6k00uQTnI+nSnBhzkfN1GaolyGbWzhcn/ZqOOM7toO5ie9SqNw2sdpPORSkjIUcD17iqRAhCg8qSR/Ojo37wZJ6L0octhU4U5zknk035SeR83qaABSyt8pwB+YNSEsxZnIJ/nTemQzc+tDZIyW5Pp0oEg8xyMjk9MUKoJZnIGKax+YhW59hjFMjyCw+8T607Etss7yck8gnvUqZBzjPHWqvmHeOhI7VKrPgnHH1pNGkZFlWJG4sTjoDUqSlgN2M+h71VRhzx9B2p6yEZyQBiocTZTsWTMVIwSFHTPakMrZ5k5P8XeqrncQA3B6k07cuetPlH7S+hbDerFx16dPepIpCCJFwrp1A6mqXmAYHUf3qRH2EFjz2pco/aGquosqYSNGPXJ6g+tSpqasmNgbA5Oe9ZJk4+UhT9OTTQR0yc09R85rx6my/dIDdM9So9qQ3ZaQsWYgjqTzWUp7jPtQkhTPynPvRa4e0sa0V4CgUk43elWElYyqyMWfOWHcj0rF3vgc7SelOFyyvhGYDv6k0Wa2KjVvua8plW586VgJcfLHjgL2FKLxihI2uMHKnjZ+NZsEjfxHG3kEn7tL5vmNIQTnqT/8AWqeXXU09p2LhZUkV+pPtxiphP++VXyIzgkL/AHazY2wwUEkDnOc5qSJmDY3DJ/lVcoe0LvmlWb7OSkZB2ljzj0NSWMrCQlmQE8FiNxrLlceZhW3kVbtLlYU3xhZZM/eI6ew9auxHtEjSnuY0iCu7yknb1PNEF0YnWOJI1b++RuwKzJLmQyyXFwCZnOAcABR9KhZ5EkPmEjzBuA9Peq9ncl4mzNsXrBzJJuJYnDZ6irInMhEbHIVenpmuZjd5VXG7ap4YnrWhbS4ZiWO1h1z1rN07GkcRc1YpSmPLI56Z7CtK7lMkcM6YKMNuc87l4OR+VYMD4ZARjHzbgeg7VI0hVurYJ6DvUtdDRPqa7T7iw3/ICM59ajkbdgHoQdxHbn0qihdppFbowyN3fFLlwpK9Bgn0walQsxudy5uWSJ1Ul9wIwFx0IqaBvLlikVcbvkwaitfNyiv5Xlk/ePOKmhi/0f8AeEsUYMAOO9VImLOk0KURujEFk3K2PX1rbmAWOJh97eV47DOR/OsDRJCIpNg3Lu2lWAyPcVv2ZjezuEY7ZIjlSevXtXHU3Z0xNeabZaOtwSY2G1WzV/Rp0cPbtkMoHJPUVjYeWFnkJ3pjir1hIyKk8RU7CGJ9PasSmro24GeG4YNlYmH3mPP4Vm34EF4txAGRX+9g/fPv6VeEwnbjc29c56kmo7pJGOxgpQjkEUXMILW73Pjmzt3vblYEkijLkAvK4RV9yT0FF5by2kmydNrdRn+Ieo9qrjD8Hp6U+Sd5H3SOzNgDLHJA9Oa9RWPHuOjbGF7etK24YGc4PWo8FVyCDQGwQR196VkPmJC5AO315p3mbhxzUTdskH6U1icccU0gcicvwMA0gkJ+XA46ios4GBk05IJHLMBhRwW6CnsTzXJTnqORSbj2zz71Gw2HGeDzxQo4yvamkLmJGbLDnkUkjHcM8cUwY9fxoDj2P45p2E52JNw4KknNG8+pqHIJ5P4CgtkcgDHSjlJ9oS7sj5uPpQZSDgAY9Kh3kn2pV6nnrTsHOyXo3T8KUghSMY9R61GOvXkU/JIGWosPmFTAAJzUhbkbugGB7VHuBOMZFNkYkYzRa4c1iwpIPXinhsMCenSqIypHzE1ZU/KcYzScSo1Lk3I4AyBzSsxyu0ZOM1EGyDyc9KUEKuMDPY0WL5h6bsHIpxwVAHOOMVB0B75oBO0YPalYOYsBjnnGPSgNycioxgdTzQx7ZI+lPlDnJXc5+UY9qCxPLcAUzsOpP1oJY4HbNFg5yTcCwLHn1p4YDnv/AEqHgg5x9aVDuJz1Hf0osUploOM4OMdQCelOaQKvQBTVUkAZyD2pGyeO1Fh+0stC0kgc8EqMc49aRpdrAx5Hbnn8qrA4G3t396TcSO/tTjEl1GXElEbAxnce+aRJfLui8TZHrnoaqI+Bx1PQ1sWGmxtfwCWRTEcF3HATI7/4VpGNzJ1CO3jnuJCqgsQcnH860rzTWa1hlVlQ7MFcfePsa3bEW1nqYkgMSROChL9xj730qtdh7XH+kxzWzEtGwGQPatuVJEOVyjHpD/2CJoZFeQyBNqjkf/rqvLZ3UCytNAyKhBY/3fQVuieOAzRW8kbhEWQEDjcOakOpny5opCssbLtYY7n/AA9aUopopVGjmoCCCWJGSAOfetG0mK7vkVhg/wCTTtT0+3W1+0WjEIFUAE9W71UgmblSRuY81z1KZ20q1zQjcNJEyDHBO709qeC5cvkH5RnPY1WhlEaIUK7d2Dk9T60/zQyE8EA44rJnUmma+nLC0YYsvyHLN0A/Gr0Cql5JG2104YBTwcj1rItnRmMRQL8u4n+9+FaaTpviKgfMMccVjK5cUbekhY7uZJORhSO2K2rZJFaS4gRZRGMuD0xmsWxdBfB7jAQx8EdxW/DPJtTywkcQTAEfIYZ71zTWpstNjYtYkntS+/Kk5cjsvpUk9n9kCiNcwscL7fWqml3P2ZHgyvkznp/dNdV9nWWGBdoBHzEdelZWJnUcNzHsGMCFCWJByG9Pars/MJdiAwNRXdusZ3EgK3K/WqU842AFizdcGhD0l7yPjt1MeAzDNNJHUHim7sjrnNNLZXIr1rHzvMSZyOOKCxGOcmoy2R9KfjI56U+UOYeX565o3BhjpTNwxwBn1phbJ/8ArUWDmLAZQuNp9zTmlZ1wG4qAZ6GkHXFFhcxKWx0GfrQHAPOOfemZHNNOeuM1aQuYkLheVOf6VHuIQt1ApO2MYqRYiw5+UetFiWxqtu5XIFBz1ap1hVF659800qCOuf5mnYm5EvJ4zTx0JBpuMDgmgjAyBzRYq5ICeKcDmowT07YpQCVHPWiw+axKDwT2pCAQOOKbnB7U4McYJ49qdrBzXEUHtUobHHGKYvTjP9KXA9DUtDTJFyc8/Tml68Y6UzsPbpQMjJ6UrFcw/HA9qTngZHp1pu7/ACKXjPSnYOYkHpThz161EG96dkE5yfSiw+YlAOM5o+6o570wHI2jOD3pxI6Z4+lFguKOW4wBT+MnB5pgyeRTk4bDGhIpMMc9KeOSd2DimM2Wp24kY7dqLDuI/BAb5R6U2L/SZ444h87nauTgE+57VJIJGhZOqbcnjpz61EnmLbRsB+7LHBAGc9K0ijKUmTRx7ZWVsEqM4qzPfXP2dF3bUBBCj1Hf61FC+ZzkDDfL+NOu7WWABZY2TJ43KRuq7diLl+S6FzBLJI7m5+Urxxx1/SoPtMlxEYYyw2/MqZ6mqaw3Jid1jk8sdSRgfjRYNsmTIOM/pQkO9zrNKTFuv2kPG0YYgFf9Yx/hNVLaBpLg8ks4C7BnB5/lTor6VnaeQkMBtU46Cr9jIEtWmV8Z/uHBDDoB7VorAiG+gVZ7S3WZQFJJzkAH096zLnfaXswJBcMRx2rUsmivp7yaeTAhT5CecHuax5sPOgdg20fNg9eeKzmtDWErMuRfvYxtUbh3JxVlARF8gySeOKpQOr7ihGzP+RV2CQPAyID85wM/rXJJHowkOknYzKdxAHGRWzahdqNLIoUEFkH3vp+NZfkiRjGOI1HDe/0/rWpCu/f5UasiR9ByTWbsbRZrR3Edw5Mh2sFwjIOPp+FdPp8iLbTrI+JY8Kp/hZfWsPTdK+0y29rExkLASSOBgRgDua37fSZrreuCkanl2HQVzztc3i7blhIHki3qGAccN/CpHvXR6BqhOY3+YgY3VnxhkjhtFQiGMbVHr7n3qd7NbWRCCFXPReprnfkU4prU25V8xZNyjYeRmsTU4zFlxjJ6AVaN+ZYdoHIFZOqXzPGi4AY9B3/GqirsiOh8gkcUoBCgj1o8yPaMZzSeaPQmvXsfM3D7rU4Ank9KTzhj7g/Gk83jAAFKwXJAp7U7YxHNQ7ye9Lvb1NOw+Yl2HjrmnbQPvVBuJ6k/nRmmK5KQBjkfnRlccH8qjooFcmDgAdTQXzUQpwoAk3UbqZSimIXj0pwbHYGm0oosMduz2FKGwegptKKAFJDD7opwOO1NpaAHB+vAxShuelMpRQFx6lcknOaUYLdaYKWgdyUxP1CEj1FR/hQCRwCRQOue9Fh8wpHouTSgH0oyaVe2c1TQKQ/PpSDv6npQORxR371NirjoywHUU/OaZ6YpR9eadhqQ7J71IGPHOTTFHHWnAYye1KxVxXZxwCcHqO1OgRWiY/MFHUHpzUP8J7VNa8ggnC8bue1VEl6k8JELbo1UY6A/zqxc311dqhurmVxF/qwzfd+lV/l3MM/L1yOaYZOowpz3PpWpFzUNzNcBkDtvZQG54I96hmcPaiNkRfLOQQOv41HEzbiQx3YAwPSkdz6cE85ouMI5meARkkHpmr0zNa2qojbgxwBjuay9xRt3r2pzzyShUznaaExM0I7p7WIRKoG4YkK/eYE5qrFzM4QbAeOai2u7v0wgAJzzUkGAPlPI5JPeomzamtTRjVREAMZ25bHYVowBYhvKhiVwo7DP9azrReSxztHLk/yFb1jEoSGby3eaSTjjAHoFHc1zSPRply2tWNtiFXMvG4kcIPr/AErY0exnSOS0RUEzHezD+LPYe1NtbaWRX8tJN+8ZU8gH3rRGnXbzN9mVh5OAJegz6CuVyudcUbOlaPqUCo1u6xBhyFOTgetdRpd4qBLOaIKzMCXf+I9zXL7b2xsna2u3mkbiUFcY9garRajcm4TzSR8uM+9YzT3KXvaM9BMCGUshBBOQQeCaq36pKJGjbLR9cEjmsGw1FgAJHAAx8oJ9a0FuhG7SKAcAjB+71rO3QvlaaMl5WEzcFMjBDHrWdqTsBkDc2CTjnFbWsQJKY5FkXB42j+dctrLCO3ZVmDP0JFb0lqKckfMo9qUUgFLXoHywtFFGKYAKcKAKcBQAClAoApwFMLiYpcU7FKBQIaBTgKXFKBQMTFLinAUu2gBoFKBTwtLigBgFOAp2KUCgBuKMU8CnBaaQEeKXbUm2l21VgI8UYqQKaXbRYCMClxUm2gLQkAwClFP20u2nYCPFOBI9x707bRiiwxAfwpzAjjikxSrx0pWBMASB93ApQ2TgnAPXNSKyn7wwfUU4pwMZIpNGiZHgFc5x24703lSuACnf2qfBwMD86QqQeR+VNaDHrENmRwD09qZ5e1CCPlFLG5hO1uVqUFJclTz3BqiLCQyGPOGx9aUy7xginkDL8Lz700BFxk0xjdhKnrSpk7uOB3pWkxkAZ96SNXlzxtQfrSbBJsfApaQkn5c9ezGr1tbmTAdc4ySq9adbWzSBQiHHqBmtSG2UFRGQCF2ySN0BrGUjsp02VrZeY5JFIj+8BjG4g9K6jTIHln+0uMIPnCg4VB6L/jUGk28awm4lxJ5X3d4yuD/dHrXSWenSTGJHOJZmDMO2P6VzVJo7qcO5b0i0lZylq485gTuJ4HeussE8uzWzV9y4w7ep9R6VQtrEiGdLSN3kb5SQOAPSprGwuPl3ZDE5I9BXI2dSSZdsbTfOI05I7nncasXelRCV1Khj64+7S2sv2G4kHB3ZC49fSr1k8ktncZJSRmI+b1qfIWqdznJtLlWRnhBZV7d6sW5VoTCBvcgH5uGLDsK1ZJFjH7w8kg/KePauf1y9iy+5WEic5QDP1qoq7Kbe5Xu50U7FYsx6gHkeorlNccLCXHQ+verV3fxYOQGQjLKucg+ua57U7qW/mVFYk52oo6/gK7aFL3rs5a9W0dDw/FLilxSgVueAJilApcU4CgBoFOApQKUCmIAKcBSgU4LQA0ClxTwuaeEoGRgU4LUoSpY7eRz8iM30GadhEAWlC1s2fhzVrsgW9hcPn0Q10+k/CzxNqIVo7BkQnG5zgCqUWBwIWlCV7jp/wD1Row99ewxZGcKM/hXVaZ8AbBGAv7qVuN2QQBSaSFzI+ZhGTThET2r63s/g54UtpCDD5xUbiCSa3NP8A+HLWVfI0qDcvXfFmhWDmR8Zw2M8v+qhkf8A3VJrVsvCmt3v/Hrpd3J7iM19s22g6TbxIVsbZN/ygqoAz7VqDy7VNiwRpGOmwA5qHUS0Qcx8V2fw08VXS5i0ifHvgVp23wf8WTY/4l+zJx8zd6+xXkijwdmxSN3Tmmi7G8kKwTGRtHWj2j7Cc+x8lx/BHxWxx5EIP+/VyD4DeKJM+YbWP0y/WvqSWW7VP3J43AkY5x6CpopZWkk3k4BwPX6VPtGHMz5Yf4B+KAcK1oT15fFUJvgn4sR9sVtFMQ+w7H+6fevrMECQhlbdkKAT/hS+VI+fJkeJmbczMoIYDqPaj2rHzeR8gT/B3xjECf7LLAf3XBrCv/AXiWwJFzo92uOSQhI/SvuGKJiiqcd/m/8ArVNIhMZGM4GDk9aftg5j8/bjS7y3/wBfazx/78ZFVDEfSv0An063uVkS6tIJemFZQRj8q53Vvhp4V1PJn0e3jyTzGNppqtHqO6PiAx+1Jtr6o1r9n3R7lWfS76e1f+7INy15v4g+BvifTtzWccV/GOnkt82PoatVIvZgeQYpy5U8dPStbUtC1DTJWjvrOeB1OCHQiqBjIqikNUq/c59KcEL8AEnpgDNGz8DUsLFXGTtI6N6Uy0yLysjDjHoKieBhkDvWj5ZB3YzmnCIkjAyfeouachmqhJ4BLHtT4raRycLjJ79K1VtwhwSuR1xzVgQMqj5V2gdWP8hS5i40jOt7NS4wQxI79KtwW6hRxkZ4I7Vbjt96BvvKPXitG3swoVppAin+EDOP8KzlNnTTo2KdrFhvLTcinpgcmtu3tC6QLtjVdpJjBzz6sf6U+xgeaRltIky3DOx4A+tbVrohSRDO64xlFGR+J9axnOx1RjYXRLCOZw8iGQqM88DI6cV2NlAsUnmvhmwAR6E1jW5SzjWPcsjEbmZTnjsKnGpS3bJDAm5iDnHauWV5G6Xc6JtS8lGhtYySD27morm7li27YyGVMNz1PeqmkmG3C/a3bK85HIzVs3UTKANrENgccGo2KuilI87XJaYj5yCADgCrtvq0gPlOwG3qVHWorp0d1OwHnAIGSPxqk1sSwKn5VGPm69avluPm7l+8uJ2X5XEUZPBI6+2awtTEjyhZJDgA4wOBUtzci3QqzhnB4HasDU9RZweOTz19K2p029jKU7Gdqk8ccki22VA455JNeg/BTwZ/aF0uvarGTDE+LZCv329fwrk/Bvhm58Va0trFlbdf3lxIOqr6fU19NaVZQ6fYQWtqipDCgRFX0rrnLkXKtzyMVWvomfmwBTgKcFp6xk9BVHERgU4Cr9tpd3cEeTbyvn+6pNdJpnw/1y9ZQLVow2OX4601FsVzjwhp6xn0r1/TPg1fyPH9qmChuyLmu10v4J6dEM3byyE9MnAq1TYuZI+cEhZiAASa1dO8PalfsBa2c0meMheK+ptG+HOh2UgAtUDKPTJNdXaaXY6fsWKFWVcYzgUclhc6PlvSvhT4hvSN1usIP948iu30b4FsW3aldPsX73ljH4Zr3qWWDyyyozOp+bYMYps122fNd0SCMZ5H3fr6iqSS6C52eeaP8GtAtm/fxM5PKNI2Qa3bbwlplndWkVhpdqbUlhcMw2vGAOCPXJ4rpTIGiUrJ8hG4Ec7vp7U8yqw2FhlRnkc4+tGvQnmfULSysYSfKiSMdPlAy3vVu12fP5aKW/uDp9c1ks6ICyJKW+6Xcff9yasiYPIoYjkYVE6H8alqQzQaWSTYrZQKDlCRk00SpjaRIxI+6v3R71WaKaTiPKkDaWXrj2qe204RtyG7BF6fiah8qQEn2xBHKx/efJgZIxSxzt5ZYttBHUD7tWo7AlmLKBkYGen5VZi02NWZmYksMYHSs3OIzMRyU2FjK68nB+VR/Wl3yOBHGibjjoS3NbEdjGucjOep9akihjjCBFAC9Paoc10AzZFme4VgkTSNzj04q00U+BtkQMOMAcVc2Dfk4zTto9KhyuBXaDe6lySB0AoS3jCsNuMnNWMGkwaVwDb3VVB9aXqxpR0pADmkAAYNOPQ0lGaAGhfwoIp2RRkUAL/D+FMwfcU7NANAFO/060v4jFe20NwjcESRBsivNfFPwR8N6sryacsmnXLcgxnMYP0r1bcD+dQoJfMkLspTjYAOnrmmpOOw02fI/jL4PeI/DpaSKEahajnzbcEkfUda88kt3icpIhVhwQRgivvuRwhy5UL0JNcl4w+Hmg+KEZ7y1WG6YHbcQgKwPqfWtoV7/EaRmup8bQsV+VslPSrKRqwygPPqetekeMvhDrmgB7izj/tGxXnfCPnUe6/4V54QIHIkXvhlYdK1bvsddNroSRREfKXUA+gFWYFQSLjYWPHTdVq2sg9vHJDFvjZuJOcH2rQtbWRDyioR3xWEpWO2muYrrbXLxHbFHEqnHzdTVm0sVBRHdmck5Ve9atvp6y7XLl1HBz3960LewhgwIh87Hlu/0rCVQ6o0zPsoXULHFGMA546VqQwzszM4YnPGT/SriR/uttuoAGN3+0fWpEilEnmBSSo4xyAPesXJs1UUiew0YGNvPO0N1I6/SpjClrtjt0Cjkcc/jVEXUroY45gXXsCcmrlsryZZyC2Mbc4INSxqOpRninYnyyNvf1qRbYpD5kjHardMc1Z2MQuyZgB1yOhqe2RCjRvIGDHJ4/rVRYpJ20M83qIoUN07jqfwqs98WUlFOASSVNElpJ5pC7SEbIbqD7UwWwDMCVSQ9cZwfwraMTGUrGdeO04LO5IxyB1rLeJ550jjU5Y7FA5OT0rbkKKrKjMzj2rufhP4Xa5v21S8hBgiB8oN0LetdULRVzjr1eVXZ3Pw28MR+G9ARNo+1zfPM56k+n4V14HI4pMHsMVJWDd3c8aT5nc+SND+CsLeWb2eRyfQYrtNM+F2iWiFxaq+04ywzXbSXCpkA5B7L60x7nakqiQKXTgOfevW5EiOcgi0PTLKLy44IgxGAAAv4cVdhS3t8LFBwACQf5ZquZEk3NMWGOAccZpy3HCqpxGclQvGD9fSiJG+5d84oqkIVGAAemaU3aohXcGZTn61nPMJMnBJHy7mPGabFKrnOwDadu71IphY0Yrpn3sq9eMHoKbLIUCsHYRkYOOoPrzVZbWa5chGIZvmUCrsemMdm8NJITkY5A+tQ2luNIaksUce9XZ2646nPuaI5JVXcVTn5ssOAPTH8q0U0hYSqP5eOjhT3qa7hjhS3bypDH5yByf4uuPwrKVWPQqxlWcdxLG8CBhKi4wwwQD0qeXQbu6jiSO6NtIGBduu4DtXVrGEnTbtGQclRj6fjUjRj7SGJ+Y8HFYOu+g0jHttIgVChy7KCoO7I5qQafiZtvMQXIB7ewrWhVACiDaR6UH5HPptxis/aNgMgjUgKoCqOSq8CktViLsYZC5U4Yk5x7U+E8YUYOaULHFKzBVUnqfU1ncY8g79oXIPO7PSlXgc/wAqTefOICErjrTkLE8n8KQDgwxSUHrRQAADdnnNOptLmgBaKTNKOlABmijFJnkj0oAUHNI1AwKbK6ou5jgD2oAWiojMNm5AWz04pElLD7hzQBOGBGAaQdaSMNzuAFKeDxQAnIB470EjGe3rSKGB9RTBG5mZnk3R/wAKAdPrQBIQCOxB9aVevPNJSjigBNpB68Yx71wXjr4ZaH4nJm8oWl+TzNAAM5/vDvXfHmo5IwynLMO5I6kelNNoqMmtj5K8SaBrXw8vmtbsi60qZt2U/wBXJjv/ALLVd0ye01KEPat5jZyUP3voRX07c6dbahaPBf20U8EgOY3TII9/f3rx7xj8F0SdtQ8HXptJ+WFtI2FJ9FPb8a0bVTR6HdQxfI9TBt7VGRTtOM7SIx09yKuxpBGTBM4d/wCEg42muOu5tf0KXyvEumXUQX5RcKhx+Y4/GtGwvba+ZHhnWdT6N8w/CuedJxZ61OrGotzqPMthbJGiSC4fjOflH/66ryS5hfyXKOCMkD7v1qjFP+7UTA4HHBqSKSSMSOrK3mdR6io5e5qWLd2dpVkRWTGfMU7SxqdTsRHLEFWBI68VUikjK+VIXIA4AOKV5nk3OEVHPGR0wBS5Q5rF0hUhXnPmHpjpUK7w+QRgep4qJd7gB2ABXjJ4pAN7hC4I6YHP61cYMlzQjOA4BAUZySOh96gkJBO1ZAv3QSMk/Sm3es6Vp8qia4Es4+URRfM+foKvaTofinxIu+1sxomnNz9rulzKR6qvaumMbbnHVqxW7GaHoh1XWIbJWxvIL8fMo9T7V77plnFYWUVtbqFjjG0Cue8CeFrLw7YMLbzZbiU5luZuZJffPp6CuqHSpm9bI8mvVdSQo4FFJRUGB48kuxyd4BIzlT6e1OlljZQdgI4Kljgn14ot7FpJdu3APHvVtLBWRHYAoZBhSema9luxnYqpI7kKoZzjJ7Afgatw2086FwuI87SD2FXUgjS4ePy8upGHFaWmxSeXI0yGNN+7LHiolUsrhYy7PTiwMZG4D5hxWta6dCsEm4R+ZtzhuceuKm2j94qPkLyW7DPp71PEgigjjAGxicM3Rj9a551GyrEVkokxJCuwRgYLHGexq+6r5R2bQVbJ2jNMtEUxMq5OPkyegPWrMAVWZURDuYBnUH+VYSldjSHiKMSxMIyCwPJ/rVTViWubW1DHc0wkOBwFHb61b/evOuPliQ8DuKlu0KkS8kK2SAMk1lswsNKnynKueWByRj2qVVVRnDsc5z2oIVFbJyucHPUe1AY5QBMqaQx4ZijkDaSMgU3BwpYrnAoIfYdpVR6egpvDBFIBkx1xxQBMCOgcD8KYeP4cjOSaSBRk5U5757VKeEOADzSAAD/ETmlPGMVFJKEhZ+eByaabhJMpHKA5BK5FAFrAptRJOCGYHKjjPqaYzyOG2DBxxQBPSnAPNVisquCWLLgZA9ak2vuJ3Z46HtQBLwelGaYpI+9gUrONrH0oAeWAHzHFJ/E1Z0upWynYzhpP7mefwFQjVDJIyrEwx1YHINNK5XJI1toPtQMDPB6ZrNs7ma6uOApgHVs8g9uK0ywHWk9BNWGoyyKCueelO5AwTSAA/d4A9KcBxzQITDZ68UrCloPSgBBz1oYZ4BwaSjvnvQAfjTXDfLsx15z6Uc7sBPxqC7mMMUh++4Ussan5nIH3R9aALEnC7g2AOT9KRWBAZeQfWqVnPLJBC08RhkdQXjLbvLbHQ1Y35cDtTGK7jBDlgD6VCwLMxK7iVxj2pzKzkhCQSCAcZFTQR7VGSN+ACR3ouF7EDQb1COqshHzIwyCPQiuP134YeGNVd5VsBZXLHIltH8s5+g4rvRxTSvNHMylOUXdM8au/hJewo7aZ4hdhj5VuIQ36ismf4b+NISvl3OkzKOm5ima95AJbBA2djSCPeCGPFPm8jdYyqla54F/wrvxsDlU05sgjIuMY/Sp4vhz4vBUFdPYY5JuThf0r3dYwnQ57UuB6DmjmH9dq9zxe1+GniOQoJ7/SrcjqAjyn688VrWvwispAratrF9d46rDiJf0r1IAA8ACnjpxRzMzliakt2c14e8F6BoDh9N0q2jmHHmld0n1LGtu4+dvKUspPVx2NSyMEQscjHGB60kI2kqeWPLGld9TFtvUfGu1QPTjPrS5p1GKQgHSiiigDzy2GXY9Nx5x+NWreCPyY+MiNwAPxNFFelMhE8qiS4nQjarDnbxU1nEqQz9T8ufmOaKKxlsgLNo25+VXmMHp71btlCiUdVA4U9OTRRWT2KHQqphY7QMt2qU/utwTg7Tz3oorPqANIditxnbu/GpdRdl0+4lViHjiZ1x0yFJFFFJjKPh+aW60GznuHMkzopZiAMkjrxWtgLnAxgYoopAZ+qzva2sckWNzyBWyM5GelXpG2RyFcZGKKKAM+5mkMn3sDHQUyNma3lJY5Q/LjtRRVASwMXKRMcoetSLGssK7xnk0UUMCyqKqHbUgAIHFFFSwHDg47U0jlm74oopARXTbLZmABIA6153r2sX11ez2TzlLd2VSqDBx9aKKDegk2ZN4Ps0/mxk+YkoXcTkkehru/DQF7ZQXUwHmY5Cjg/WiilFnRiPgR0MWBwAAPQU/+I0UU2cD3HL0paKKAK12xVosHrIo/nU46iiigBXOEJHXFNhJaME8k0UUAObrVedtoLgDcvQ4oooArxHOW7nrVpEG3dj5vWiiqGOpyjjNFFIB46U09aKKQgHWlfp+NFFACjpSN1oooAQDHPegdDRRQBDktdgHoE3D61OtFFAC0UUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bullous skin lesions of the lower extremities caused by Fusarium spp in a 15-year-old girl with aplastic anemia. The patient presented with Fusarium sinusitis with subsequent development of cutaneous nodules on the face, extremities, and chest, and bullous lesions on the lower extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nucci M, Spector N, Lucena S, et al. Three cases of infection with Fusarium species in neutropenic patients. Eur J Clin Microbiol Infect Dis 1992; 11:1160. Copyright &copy; 1992 Springer Science and Business Media. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2162=[""].join("\n");
var outline_f2_7_2162=null;
var title_f2_7_2163="Atopic dermatitis popliteal";
var content_f2_7_2163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented, slightly scaly patches and lichenified plaques are present in the popliteal fossae of this patient with atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2163=[""].join("\n");
var outline_f2_7_2163=null;
var title_f2_7_2164="Placental CMV infection";
var content_f2_7_2164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cytomegalovirus infection of placenta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph illustrating placental cytomegalovirus infection. A and B arrows point to cells with nuclear inclusions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2164=[""].join("\n");
var outline_f2_7_2164=null;
var title_f2_7_2165="Diffuse large B cell NHL";
var content_f2_7_2165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse large B-cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph node shows a diffuse pattern of involvement, with loss of normal structures such as sinuses and lymphoid follicles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2165=[""].join("\n");
var outline_f2_7_2165=null;
var title_f2_7_2166="Ponatinib: Patient drug information";
var content_f2_7_2166=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ponatinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     see \"Ponatinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15847938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iclusig&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15863896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4085520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise your chance of having blood clots, a stroke, or a heart attack. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems in some patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15863898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15863897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4085508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ponatinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to lactose, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15863902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant, do not handle crushed or broken tablets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15863903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15863904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15863900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695715",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or melt.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15863901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15863905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15863906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87617 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2166=[""].join("\n");
var outline_f2_7_2166=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15847938\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863896\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863898\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863897\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863902\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863903\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863904\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863900\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863901\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863905\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863906\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=related_link\">",
"      Ponatinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_7_2167="Diagnosis and treatment of hypophosphatemia";
var content_f2_7_2167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of hypophosphatemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2167/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2167/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2167/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2167/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/7/2167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;True hypophosphatemia can be induced by decreased net intestinal absorption, increased urinary phosphate excretion, or acute movement of extracellular phosphate into the cells. Spurious hypophosphatemia can be caused by interference of paraproteins with the phosphate assay [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal renal response to phosphate depletion is to increase phosphate reabsorption, leading to the",
"    <strong>",
"     virtual abolition",
"    </strong>",
"    of phosphate excretion in the urine. Most of the filtered phosphate is reabsorbed in the proximal tubule via the sodium-phosphate cotransporter in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This transporter uses the favorable inward concentration gradient for sodium (the cell sodium concentration is less than 25",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    well below the 145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    concentration in the tubular lumen) to drive the active reabsorption of phosphate from the tubular lumen into the cell. Phosphate depletion leads to increased gene expression and synthesis of new transporters, thereby enhancing the uptake of filtered phosphate into the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypophosphatemia is often evident from the history. If, however, the diagnosis is not apparent, then measurement of urinary phosphate excretion should be helpful. Phosphate excretion can be measured either from a 24-hour urine collection or by calculation of the fractional excretion of filtered phosphate (FEPO4) from a random urine specimen. The formula used to make the latter calculation is the same as that for the fractional excretion of sodium:",
"   </p>",
"   <p>",
"    &nbsp;FEPO4 &nbsp; = &nbsp; [UPO4 &nbsp; x &nbsp; PCr &nbsp; x &nbsp; 100] &nbsp; &divide; &nbsp; [PPO4 &nbsp; x &nbsp; UCr]",
"   </p>",
"   <p>",
"    where U and P refer to the urine and plasma concentrations of phosphate (PO4) and creatinine (Cr). Calculators are available for the fractional excretion of sodium (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or, for standard units, (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). The same calculator can be used for the fractional excretion of phosphate by substituting the urine and serum phosphate concentrations for the urine and serum sodium concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Low phosphate excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily phosphate excretion should be less than 100 mg and the fractional excretion of phosphate should be well below 5 percent (normal value is 5 to 20 percent) if the kidney is responding normally and renal phosphate wasting is not the cause of the hypophosphatemia. A review of the basic aspects of renal phosphate handling is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of hypophosphatemia with an appropriately low fractional excretion of phosphate includes increased cellular uptake (internal redistribution) and reduced net intestinal absorption (",
"    <a class=\"graphic graphic_table graphicRef71616 \" href=\"UTD.htm?24/38/25195\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased cell entry is more likely if the patient has received glucose or insulin infusions (as in refeeding or the treatment of uncontrolled diabetes mellitus) or has acute respiratory alkalosis.",
"     </li>",
"     <li>",
"      In the absence of these problems, the most likely cause of the hypophosphatemia is chronic diarrhea (in which there is loss of phosphate in intestinal secretions), or chronic antacid intake (in which intestinal phosphate is bound to magnesium or calcium to form insoluble salts that are not absorbed).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inappropriately high phosphate excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary phosphate excretion above 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or a fractional excretion of phosphate above 5 percent is indicative of renal phosphate wasting in patients with hypophosphatemia. This problem is usually due either to hyperparathyroidism or to a renal tubular defect, both of which impair proximal phosphate reabsorption by diminishing the activity of the sodium-phosphate cotransporter (",
"    <a class=\"graphic graphic_table graphicRef71616 \" href=\"UTD.htm?24/38/25195\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of hypophosphatemia\", section on 'Increased urinary excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypophosphatemia can be seen with either primary or secondary hyperparathyroidism. The triad of hypercalcemia, hypophosphatemia, and urinary phosphate wasting is usually present in primary hyperparathyroidism. In contrast, hypocalcemia is the major stimulus for hypersecretion of parathyroid hormone in secondary disease. Hypophosphatemia and urinary phosphate wasting in someone without hypercalcemia should prompt an evaluation for vitamin D deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"       \"Etiology of hypercalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=see_link\">",
"       \"Etiology of hypocalcemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"       \"Treatment of vitamin D deficiency in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Persistent hyperparathyroidism and hypophosphatemia can also occur after successful renal transplantation due to delayed involution of the parathyroid hyperplasia induced by pretransplant renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"       \"Parathyroid and mineral metabolism after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tubular defects, which are relatively rare, can occur either as an isolated impairment in proximal phosphate transport (as seen in hypophosphatemic rickets or tumor-induced osteomalacia) or as a generalized defect in proximal function (called the Fanconi syndrome). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"      </a>",
"      .) The Fanconi syndrome is typically accompanied by clinical evidence of other abnormalities in proximal reabsorption, including glucosuria (at a normal plasma glucose concentration), hypouricemia, aminoaciduria, and a hyperchloremic metabolic acidosis due to urinary bicarbonate wasting. Among the major causes of the Fanconi syndrome are cystinosis, Wilson's disease, multiple myeloma (in which filtered light chains are toxic to the proximal tubule), systemic lupus erythematosus, and heavy metal toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolated phosphate wasting may be due to one of the forms of vitamin D resistant rickets, which is usually a disease of children, while oncogenic osteomalacia due to an underlying mesenchymal tumor (usually a hemangiopericytoma) should be suspected in an adult. One clue to the presence of the latter disorder is a very low plasma level of calcitriol (1,25-dihydroxyvitamin D); this is the opposite of the expected stimulation of calcitriol production by hypophosphatemia in an attempt to raise the serum phosphate concentration toward normal by increasing intestinal absorption and perhaps bone resorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H12#H12\">",
"     \"Causes of hypophosphatemia\", section on 'Vitamin D deficiency or resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H13#H13\">",
"     \"Causes of hypophosphatemia\", section on 'Primary renal phosphate wasting'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of hypophosphatemia rarely occur unless the serum phosphate concentration is less than 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.64",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Furthermore, the serious symptoms such as muscle weakness and rhabdomyolysis are not seen until the serum phosphate concentration falls below 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=see_link\">",
"     \"Signs and symptoms of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, most hypophosphatemic patients will not require therapy other than that aimed at the underlying cause. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypophosphatemia occurring during the correction of diabetic ketoacidosis will correct spontaneously with normal dietary intake. Trials of routine phosphate supplementation have not shown benefit, but such therapy may be warranted in patients with severe symptomatic hypophosphatemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum phosphate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Phosphate depletion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have hypophosphatemia due to gastrointestinal losses should correct spontaneously once there is resolution of the underlying cause (eg, diarrhea, chronic antacid therapy, or vitamin D deficiency which should be treated with vitamin D supplementation). Recommended initial daily vitamin D supplementation is 800",
"      <span class=\"nowrap\">",
"       units/day,",
"      </span>",
"      but more may be required. Patients taking drugs that increase the hepatic metabolism of calcidiol may require as much as 4000",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"       \"Causes of hypophosphatemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"       \"Treatment of vitamin D deficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3136520\">",
"    <span class=\"h2\">",
"     Phosphate repletion regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to phosphate repletion takes into account the serum phosphate concentration, the presence or absence of overt symptoms of hypophosphatemia, and whether the patient can take oral therapy. If possible, we prefer oral rather than intravenous phosphate therapy, since intravenous repletion can lead to hyperphosphatemia that may result in serious complications such as hypocalcemia, acute kidney injury, and arrhythmias. (See",
"    <a class=\"local\" href=\"#H3136551\">",
"     'Intravenous dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      patients with a serum phosphate less than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we give oral phosphate therapy since many of these patients have myopathy and weakness that are not clinically apparent.",
"     </li>",
"     <li>",
"      The treatment of",
"      <strong>",
"       symptomatic",
"      </strong>",
"      patients varies with the severity of the hypophosphatemia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We treat with oral phosphate if the serum phosphate is 1.0 to 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.32 to 0.63",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      We treat with intravenous phosphate if the serum phosphate is less than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.32",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and switch to oral replacement when the serum phosphate exceeds 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We stop phosphate repletion when the serum phosphate is greater than or equal to 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      unless there is an indication for chronic therapy such as persistent urinary phosphate wasting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral repletion is most often achieved with a combined preparation of sodium and potassium phosphate;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    is preferred for intravenous therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3136544\">",
"    <span class=\"h3\">",
"     Oral dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When oral dosing is used, we initiate therapy with 30 to 80 millimoles (mmol) of phosphate per day in divided doses. &nbsp;Phosphate may also be supplemented with skim milk, which contains approximately 15 mmol of phosphate per 480 mL serving.",
"   </p>",
"   <p>",
"    The following regimen is a reasonable approach [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum phosphorous is greater than or equal to 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      1",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      of elemental phosphorous (minimum of 40 mmol and a maximum of 80 mmol) can be given in three to four divided doses over a 24 hour period.",
"     </li>",
"     <li>",
"      If the serum phosphorous is less than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      1.3",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      of elemental phosphorous (up to a maximum of 100 mmol) can be given in three to four divided doses over a 24 hour period. &nbsp;",
"     </li>",
"     <li>",
"      Severely obese patients may receive the maximal initial doses or an adjusted dose based upon their height and weight (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?2/41/2706?source=see_link\">",
"       calculator 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with a reduced glomerular filtration rate should receive approximately one-half of the suggested initial dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The serum phosphate concentration should be rechecked two to twelve hours following the last of the divided doses to determine whether repeated doses are required. If so, the same approach may be reapplied.",
"   </p>",
"   <p>",
"    Oral phosphate supplements (tablets and powders) contain varying ratios of sodium and potassium phosphate. Serious medication errors have occurred due to confusion among preparations and lack of uniformity of units on product labels and when ordering. Thus, an oral phosphate supplement should be selected with consideration of its potassium and sodium content and dosed according to millimoles of phosphate. Commonly used oral phosphate supplements include 250 mg (8 mmol) of phosphate per tablet. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/17/7444?source=see_link\">",
"     \"Potassium phosphate and sodium phosphate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3136551\">",
"    <span class=\"h3\">",
"     Intravenous dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous phosphate is potentially dangerous, since it can precipitate with calcium and produce a variety of adverse effects including hypocalcemia due to binding of calcium, renal failure due to calcium phosphate precipitation in the kidneys, and possibly fatal arrhythmias.",
"   </p>",
"   <p>",
"    If intravenous therapy is necessary in patients with severe symptomatic hypophosphatemia or an inability to take oral therapy, we suggest a dose that varies depending upon the severity of the hypophosphatemia and the weight of the patient. We suggest the following regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum phosphate concentration is greater than or equal to 1.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.40",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we give 0.08 to 0.24",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      over six hours (up to a maximum total dose of 30 mmol).",
"     </li>",
"     <li>",
"      If the serum phosphate concentration is less than 1.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.40",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we give 0.25 to 0.50",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      over 8 to 12 hours (up to a maximum total dose of 80 mmol).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other investigators have advocated a more aggressive approach since, in critically ill patients receiving nutritional support, lower doses similar to those above were not effective. This strategy was evaluated in a study of 79 critically ill trauma patients with hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/10\">",
"     10",
"    </a>",
"    ]. The following algorithm was used in for dosing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum phosphate was 2.3 to 3.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.73 to 0.96",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      0.32",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      was given.",
"     </li>",
"     <li>",
"      If the serum phosphate was 1.6 to 2.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.51 to 0.72",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      0.64",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      was given.",
"     </li>",
"     <li>",
"      If the serum phosphate was less than 1.6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.50",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      1.0",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      was given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each dose was rounded to the nearest 7.5 mmol for ease of preparation, and infused at 7.5 mmol per hour. If hypophosphatemia persisted on subsequent days, additional doses were given according to this strategy. On day three, the serum phosphate was normal in all 79 patients. This dosing regimen appeared safe; mild hyperphosphatemia was noted only eight times in 237 patient-days, and there were no instances of hypocalcemia.",
"   </p>",
"   <p>",
"    However, none of the patients in this study had renal function impairment, a setting in which aggressive replacement should generally be avoided. In addition, we do not usually give phosphate replacement when the serum phosphate is above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.64",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    The serum phosphate concentration should be monitored every six hours when intravenous phosphate is given and the patient switched to oral replacement when the serum phosphate concentration reaches 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     \"Sodium phosphate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/17/7444?source=see_link\">",
"     \"Potassium phosphate and sodium phosphate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52289983\">",
"    <span class=\"h2\">",
"     Urinary phosphate wasting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypophosphatemia due to persistent urinary phosphate wasting is more difficult to treat than other causes of hypophosphatemia, since raising the serum phosphate concentration with phosphate supplements will result in a further increase in phosphate excretion that minimizes the elevation in serum phosphate.",
"    <br/>",
"    <br/>",
"    Another possible approach to the treatment of urinary phosphate wasting is the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    . The observation that acute administration of dipyridamole increases renal phosphate reabsorption in animals and humans prompted a prospective study evaluating its efficacy in 64 patients with idiopathic increased urinary phosphate losses and mild hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/12\">",
"     12",
"    </a>",
"    ]. Exclusion criteria included hypercalcemia, a history of cardiovascular disease, a glomerular filtration rate of less than 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, and others that were primarily focused upon identifying patients with specific causes of phosphate wasting. &nbsp;",
"    <br/>",
"    <br/>",
"    The administration of dipyridamole (75 mg four times daily) significantly increased serum phosphate levels in 80 percent of patients, with the maximum effect occurring after nine months of therapy. Serum levels of parathyroid hormone and calcium were unchanged, but the concentration of calcitriol (1,25-dihydroxyvitamin D) was significantly decreased. In two subsequent studies, dipyridamole had no effect in six patients with X-linked hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/13\">",
"     13",
"    </a>",
"    ], and increased serum phosphate levels in 11 patients with hypophosphatemia due to phosphate wasting following renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2167/abstract/14\">",
"     14",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Further study is required to determine the role of dipyridamole in patients with hypophosphatemia due to urinary phosphate wasting. Based upon the available evidence, some but not all of the authors and reviewers of this topic suggest a trial of dipyridamole (75 mg four times daily), primarily in patients who have symptoms that might be attributable to hypophosphatemia (eg, muscle weakness, rhabdomyolysis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727383\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      True hypophosphatemia can be induced by decreased net intestinal absorption, increased urinary phosphate excretion, or acute movement of extracellular phosphate into the cells. Spurious hypophosphatemia can be caused by interference of paraproteins with the phosphate assay. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"       \"Causes of hypophosphatemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The normal renal response to phosphate depletion is to increase phosphate reabsorption, leading to the virtual abolition of phosphate excretion in the urine. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of hypophosphatemia is often evident from the history. If, however, the diagnosis is not apparent, then measurement of urinary phosphate excretion should be helpful. Phosphate excretion can be measured either from a 24-hour urine collection or by calculation of the fractional excretion of filtered phosphate from a random urine specimen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In hypophosphatemic patients, daily phosphate excretion should be less than 100 mg and the fractional excretion of phosphate should be well below 5 percent if the kidney is responding normally and renal phosphate wasting is not the cause of the hypophosphatemia. The differential diagnosis of hypophosphatemia with an appropriately low fractional excretion of phosphate includes increased cellular uptake and reduced net intestinal absorption. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Low phosphate excretion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"       \"Causes of hypophosphatemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary phosphate excretion above 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or a fractional excretion of phosphate above 5 percent is indicative of renal phosphate wasting in patients with hypophosphatemia. This problem is due either to hyperparathyroidism or to a renal tubular defect, both of which impair proximal phosphate reabsorption by diminishing the activity of the sodium-phosphate cotransporter. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Inappropriately high phosphate excretion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H10#H10\">",
"       \"Causes of hypophosphatemia\", section on 'Increased urinary excretion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms of hypophosphatemia rarely occur unless the serum phosphate concentration is less than 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      For these reasons, most hypophosphatemic patients will not require therapy other than that aimed at the underlying cause. As an example, vitamin D supplementation is indicated in patients with vitamin D deficiency. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hypophosphatemia and a serum phosphate less than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we suggest phosphate repletion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Even if these patients are not overtly symptomatic, they may have myopathy and weakness that are clinically apparent. We suggest the following approach: (See",
"      <a class=\"local\" href=\"#H3136520\">",
"       'Phosphate repletion regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      patients with a serum phosphate less than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we give oral phosphate therapy.",
"     </li>",
"     <li>",
"      The treatment of",
"      <strong>",
"       symptomatic",
"      </strong>",
"      patients varies with the severity of the hypophosphatemia. We treat with oral phosphate if the serum phosphate is 1.0 to 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.32 to 0.63",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      We treat with intravenous phosphate if the serum phosphate is less than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.32",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and switch to oral replacement when the serum phosphate exceeds 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      We stop phosphate repletion when the serum phosphate is greater than or equal to 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      unless there is an indication for chronic therapy such as persistent urinary phosphate wasting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When oral phosphate is used, the following regimen is a reasonable approach: (See",
"      <a class=\"local\" href=\"#H3136544\">",
"       'Oral dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the serum phosphorous is greater than or equal to 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      1",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      of elemental phosphorous (minimum of 40 mmol and a maximum of 80 mmol) can be given in three to four divided doses over a 24 hour period.",
"     </li>",
"     <li>",
"      If the serum phosphorous is less than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      1.3 to 1.4",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      of elemental phosphorous (up to a maximum of 100 mmol) can be given in three to four divided doses over a 24 hour period. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous phosphate is potentially dangerous, since it can precipitate with calcium and produce a variety of adverse effects including hypocalcemia due to binding of calcium, renal failure due to calcium phosphate precipitation in the kidneys, and possibly fatal arrhythmias.",
"      <br/>",
"      <br/>",
"      If intravenous therapy is necessary in the patient with severe symptomatic hypophosphatemia or an inability to tolerate oral therapy, we use a dose that depends upon the severity of the hypophosphatemia and the weight of the patient: (See",
"      <a class=\"local\" href=\"#H3136551\">",
"       'Intravenous dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the serum phosphate concentration is greater than or equal to 1.25 (0.40",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we give 0.08 to 0.24",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      over six hours (up to a maximum total dose of 30 mmol).",
"     </li>",
"     <li>",
"      If the serum phosphate concentration is less than 1.25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.40",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we give 0.25 to 0.50",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      over 8 to 12 hours (up to a maximum total dose of 80 mmol).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum phosphate concentration should be monitored every 6 hours when intravenous phosphate is given and the patient switched to oral replacement when the serum phosphate concentration reaches 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.48",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3136551\">",
"       'Intravenous dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/1\">",
"      Kerr S, Kindt J, Daram SR. Hypophosphatemia associated with paraproteinemia: a case report and review of the literature. WMJ 2007; 106:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/2\">",
"      Murer H. Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions. J Am Soc Nephrol 1992; 2:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/3\">",
"      Levi M, L&ouml;tscher M, Sorribas V, et al. Cellular mechanisms of acute and chronic adaptation of rat renal P(i) transporter to alterations in dietary P(i). Am J Physiol 1994; 267:F900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/4\">",
"      Halevy J, Bulvik S. Severe hypophosphatemia in hospitalized patients. Arch Intern Med 1988; 148:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/5\">",
"      Lentz RD, Brown DM, Kjellstrand CM. Treatment of severe hypophosphatemia. Ann Intern Med 1978; 89:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/6\">",
"      Collins N, Maher J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991; 78:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/7\">",
"      Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 2005; 62:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/8\">",
"      Taylor BE, Huey WY, Buchman TG, et al. Treatment of hypophosphatemia using a protocol based on patient weight and serum phosphorus level in a surgical intensive care unit. J Am Coll Surg 2004; 198:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/9\">",
"      Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore) 2000; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/10\">",
"      Brown KA, Dickerson RN, Morgan LM, et al. A new graduated dosing regimen for phosphorus replacement in patients receiving nutrition support. JPEN J Parenter Enteral Nutr 2006; 30:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/11\">",
"      Weisinger JR, Bellor&iacute;n-Font E. Magnesium and phosphorus. Lancet 1998; 352:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/12\">",
"      Pri&eacute; D, Blanchet FB, Essig M, et al. Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J Am Soc Nephrol 1998; 9:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/13\">",
"      Seikaly MG, Quigley R, Baum M. Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia. Pediatr Nephrol 2000; 15:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2167/abstract/14\">",
"      Balal M, Paydas S, Seyrek N, et al. Dipyridamole for renal phosphate leak in successfully renal transplanted hypophosphatemic patients. Clin Nephrol 2005; 63:87.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 835 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2167=[""].join("\n");
var outline_f2_7_2167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H727383\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Low phosphate excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inappropriately high phosphate excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3136520\">",
"      Phosphate repletion regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3136544\">",
"      - Oral dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3136551\">",
"      - Intravenous dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52289983\">",
"      Urinary phosphate wasting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727383\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/835\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/835|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/38/25195\" title=\"table 1\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?2/41/2706?source=related_link\" title=\"calculator 3\">",
"      Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/17/7444?source=related_link\">",
"      Potassium phosphate and sodium phosphate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=related_link\">",
"      Signs and symptoms of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=related_link\">",
"      Sodium phosphate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_7_2168="Prevention of neurologic complications of cardiac surgery";
var content_f2_7_2168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of neurologic complications of cardiac surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Michael L McGarvey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Albert T Cheung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Mark M Stecker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2168/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/7/2168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications are second only to heart failure as a cause of morbidity and mortality following cardiac surgery, and the presence of neurologic sequelae significantly increases the likelihood of requiring long-term care.",
"   </p>",
"   <p>",
"    Most neurologic problems following cardiac surgery can be divided into three categories (",
"    <a class=\"graphic graphic_table graphicRef68206 \" href=\"UTD.htm?16/33/16925\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stroke",
"     </li>",
"     <li>",
"      Neuropsychiatric abnormalities or encephalopathy",
"     </li>",
"     <li>",
"      Peripheral neuropathies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to the prevention of neurologic complications of cardiac surgery will be reviewed here. The clinical features of these complications, issues related to coronary artery bypass grafting (CABG) in patients with known carotid artery disease, and an overview of all early complications following coronary artery bypass grafting (CABG) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=see_link\">",
"     \"Neurologic complications of cardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6617?source=see_link\">",
"     \"Coronary artery bypass grafting in patients with cerebrovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective report from the Society of Thoracic Surgery National Cardiac Database, of over 400,000 cardiac surgeries between 1996 and 1997, reported an overall incidence of a new neurologic event (stroke, transient ischemic attack, or unexplained coma lasting more than 24 hours) of 3.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/1\">",
"     1",
"    </a>",
"    ]. A second study prospectively evaluated 2108 patients undergoing coronary artery bypass graft surgery (CABG) at 24 hospitals in the United States between 1991 and 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/2\">",
"     2",
"    </a>",
"    ]. Overall, 6.1 percent suffered a cerebral complication, roughly equally divided between stroke and encephalopathy. However, this rate of 6.1 percent is likely high and not reflective of current practice in which rates are in the range of 1.5 to 2.0 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition this study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/2\">",
"     2",
"    </a>",
"    ] lumps together delirium and confusional states with cerebrovascular events and transient ischemic attacks. Increased age was a dominant risk factor for both types of events (",
"    <a class=\"graphic graphic_figure graphicRef68686 \" href=\"UTD.htm?14/21/14685\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REDUCING NEUROLOGIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinically significant neurological events are related atheroemboli from the aorta or to air emboli, with the former predominating in the absence of right to left intracardiac shunts. Many cardiothoracic centers are increasing the percent of patients screened for mobile atheroma of the aorta. Assessment for atheromatous debris is helpful in any cardiac surgery procedure where surgical manipulation of the aorta will occur, including any type of aortic clamping, aortic cannulation, aortic valve incisions, proximal coronary graft anastomoses, and antegrade cardioplegia catheters. The intraoperative assessment can be performed with a transesophageal echocardiogram (TEE) and epiaortic ultrasound to avoid blind spots that occur with solitary TEE exams [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/5\">",
"     5",
"    </a>",
"    ]. The use of these techniques allows both the identification of atheroma and aids in real time decision making concerning manipulation of the aorta. The degree of aortic manipulation has been associated with increased stroke rates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation reduces perioperative injuries by allowing formal identification and treatment of preexisting risk factors. As an example, significant carotid artery stenosis increases the risk of stroke during cardiac procedures (with risks as high as 20 percent estimated for patients with significant bilateral carotid disease); the risk of stroke during cardiac surgery in such patients may be reduced by performing a simultaneous carotid endarterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6617?source=see_link\">",
"     \"Coronary artery bypass grafting in patients with cerebrovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link\">",
"     \"Management of symptomatic carotid atherosclerotic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16922?source=see_link\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carotid stenting procedures to reduce stroke risk may be useful in some patients with carotid stenosis, but the efficacy of this procedure remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6617?source=see_link&amp;anchor=H17#H17\">",
"     \"Coronary artery bypass grafting in patients with cerebrovascular disease\", section on 'Carotid artery stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preoperative carotid duplex imaging should be considered in patients with an audible bruit, severe peripheral artery disease, or a previous stroke or transient ischemic attack [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/8,10-12\">",
"     8,10-12",
"    </a>",
"    ]. Even if carotid revascularization is not planned, additional knowledge concerning the risk for the individual patient is important for intraoperative management decisions. Special care to avoid periods of sustained hypotension and to maintain a relatively high mean arterial pressure during and after bypass will improve cerebral blood flow in the presence of significant carotid stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing CABG, the benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy to prevent thromboembolic complications have to be balanced by risk of associated bleeding complications. If aspirin is stopped before surgery, which does not appear to be necessary in many patients, it should be restarted within 6 to 24 hours after surgery. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-operative atrial arrhythmias, including atrial fibrillation, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link&amp;anchor=H13#H13\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Prevention of AF and complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Minimally invasive surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques to perform CABG without the use of cardiopulmonary bypass decrease the invasiveness of the operation, shorten recovery time, and eliminate complications of cardiopulmonary bypass. Both randomized trials and observational studies have compared outcomes, including neurologic outcomes, in patients undergoing minimally invasive off-pump CABG (OP CABG) and conventional CABG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link&amp;anchor=H4#H4\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Off-pump CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of randomized trials have compared the incidence of neurologic complications in OP CABG and conventional CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/13-19\">",
"     13-19",
"    </a>",
"    ]. The following observations from meta-analyses address the issues of stroke and neurocognitive dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 41 randomized trials of almost 4000 patients reported a 50 percent relative risk reduction of stroke with OP CABG (95% CI 7 to 73 percent) that reflected an absolute risk reduction of one stroke per 100 procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second meta-analysis of 37 randomized trials evaluated rates of neurocognitive dysfunction in 3369 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/15\">",
"       15",
"      </a>",
"      ]. There was a nonsignificant trend toward a lower rate with OP CABG at 30 days (odds ratio 0.56, 95% CI 0.21-1.54) that was not maintained at one year (odds ratio 0.91, 95% CI 0.57-1.46).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ROOBY trial, which was published after the meta-analyses, randomly assigned over 2200 patients to either on-pump or off-pump procedures. There was no difference between the two groups in neuropsychological outcomes in the 1156 patients with test measures at baseline and at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link&amp;anchor=H4#H4\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Off-pump CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies suggest that high risk subgroups may show more significant reductions in cerebral complication rates with OP CABG. These include patients with triple vessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/21\">",
"     21",
"    </a>",
"    ], severe atheromatous aortic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/22\">",
"     22",
"    </a>",
"    ], peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/23\">",
"     23",
"    </a>",
"    ], and octogenarians.",
"   </p>",
"   <p>",
"    A lower rate of embolization is believed to contribute to the lower rate of neurologic complications with OP CABG. This was illustrated in a small randomized trial in patients assigned to on-pump or OP CABG, in which there was reduced retinal microvascular damage, a lower frequency of transcranial Doppler high-intensity transient signals (HITS), and lower S100 protein concentrations (a marker of cerebral injury) among patients assigned to OP CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiopulmonary bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three aspects of CPB appear to influence the risk of brain injury during cardiac operations: temperature, acid-base management, and blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bypass temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic hypothermia reduces the cerebral metabolic rate by a factor of three to four for every 10&ordm;C decrease in core temperature, and may provide protection against transient periods of cerebral ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/24\">",
"     24",
"    </a>",
"    ]. Randomized trials comparing the safety of normothermic and hypothermic CPB have produced conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Nevertheless, moderate hypothermia in the range of 32&ordm;C is commonly employed for closed chamber cardiac operations that require CPB, and 28&ordm;C for open chamber procedures.",
"   </p>",
"   <p>",
"    The possible protective effects of hypothermia cease when rewarming on CPB is initiated. Rewarming should be performed gradually to prevent an increased risk of neurologic injury from central nervous system hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/27\">",
"     27",
"    </a>",
"    ] and air embolus formation as the solubility of gases in blood decreases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Acid-base status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia alters acid-base balance, which in turn affects cerebral blood flow. The two main techniques for regulating acid-base balance during hypothermia are called alpha-stat and pH-stat [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/28\">",
"     28",
"    </a>",
"    ]. These techniques differ according to whether pH and CO2 are based directly on blood gas measurements made on blood warmed to 37&ordm;C (alpha-stat) or on values corrected to the patient's actual temperature (pH-stat). pH-stat management requires the addition of CO2 to the blood during hypothermic CPB, whereas alpha-stat does not. Thus, cerebral blood flow and possibly the risk of embolization are greater during hypothermia when pH-stat is employed, since CO2 is a cerebral vasodilator [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/28\">",
"     28",
"    </a>",
"    ]. In comparison, cerebral autoregulation is preserved with alpha-stat management and, in a randomized trial of 70 patients, the risk of postoperative cognitive dysfunction was significantly lower with alpha-stat management (20 versus 49 percent at six weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mean arterial pressures between 50 and 70 mmHg range are common and are well tolerated by most patients during CPB. However, higher mean arterial pressures may decrease cardiac and neurologic complications and may be desirable for patients with hypertension or known stenosis of the cerebral vessels. Relative hypotension during surgery has been linked to cerebral ischemia and infarction; this may be mediated in part by reduced clearance of microembolic debris from the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been concern that higher blood pressures may increase the risk of intraoperative and perioperative bleeding. This issue was addressed in a randomized trial in which 248 patients undergoing nonemergent cardiopulmonary bypass were assigned to mean arterial pressures of 80 to 100 mmHg or 50 to 60 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/31\">",
"     31",
"    </a>",
"    ]. Higher pressures during cardiopulmonary bypass was associated with a significantly lower rate of neurologic and cardiac complications or death at six months (4.8 versus 12.9 percent) without an increase in bleeding or in transfusion requirements or a difference in cognitive and functional status.",
"   </p>",
"   <p>",
"    Acute increases in central venous pressure, caused by poor positioning or kinking of the venous drainage cannula, reduce cerebral perfusion pressures and should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all nerve injuries are not preventable, proper attention to patient positioning and padding of potential pressure points can reduce the risk of injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac surgery patients are most commonly placed supine with arms either tucked at the sides or abducted at &lt;90&ordm;. Care should be taken not to abduct the patient's elbow more than 90&ordm; and to avoid resting the arm over wires or the edge of the bed.",
"     </li>",
"     <li>",
"      The weight of the head should be supported with a cushioned pillow, and an interscapular towel roll placed to extend the neck.",
"     </li>",
"     <li>",
"      Minimal sternal retraction should be employed to reduce the incidence of plexopathies.",
"     </li>",
"     <li>",
"      Putting the patient in the Trendelenburg position intraoperatively may decrease the likelihood of cerebral air embolization, especially during open chamber procedures prior to the separation from CPB. In the Trendelenburg position, retained air within the cardiac chambers and aorta collects within the aortic root, from which air can be vented prior to full ventricular ejection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"       \"Air embolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intraoperative monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several intraoperative monitoring modalities have the potential to reduce the incidence of neurologic complications during cardiac surgery, including transesophageal echocardiography (TEE), electroencephalography (EEG), transcranial Doppler ultrasound (TCD), and somatosensory evoked potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/32\">",
"     32",
"    </a>",
"    ]. No convincing evidence exists that such monitoring reduces the incidence of neurologic complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     TEE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative TEE may reduce the rate of intraoperative strokes by detecting the presence of a patent foramen ovale, left atrial thrombus in patients with atrial fibrillation, retained intracardiac air after open chamber procedures, mural thrombus within the left ventricle, severe atherosclerosis of the thoracic aorta, vegetations in patients with suspected endocarditis, prosthetic valve thrombosis, and proximal aortic dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Because it is superior to palpation for detecting the site and severity of atherosclerotic disease, TEE can guide aortic cross-clamp placement and construction of the proximal coronary artery bypass anastomoses to minimize dislodgement of atheromata [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/34\">",
"     34",
"    </a>",
"    ]. Minimizing the manipulation of an atheromatous aorta will minimize the chance of emboli and likely the incidence of stroke.",
"   </p>",
"   <p>",
"    As noted above, large or mobile aortic atheromas detected by intraoperative TEE or epiaortic echocardiography are associated with an increased risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. This observation provides the rationale for possible benefit from aortic endarterectomy in such patients. However, in a report in which 43 such patients underwent endarterectomy, the incidence of stroke was significantly higher than in those without endarterectomy (35 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     EEG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroencephalography (EEG) can detect cerebral ischemia, since the frequency and amplitude of spontaneous cortical electrical signals decrease when cerebral blood flow falls to critical levels. The utility of EEG during cardiac procedures remains debated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. One retrospective review of 3328 patients undergoing carotid endarterectomy in 46 institutions during 1981 found a significantly lower risk of postoperative stroke or death in patients who received intraoperative EEG monitoring, although cause and effect have not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transcranial Doppler &mdash; Transcranial Doppler monitoring of the middle cerebral artery during cardiac surgery can detect arterial microemboli entering the cerebral circulation, which is most frequent during placement and removal of the aortic cross-clamp and the aortic cannula [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. The number of microemboli exceeds 60 in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/39\">",
"       39",
"      </a>",
"      ]. Although the absolute number of emboli found on TCD does not directly correlate with the risk of stroke or cognitive impairment, intraoperative somatosensory evoked potential monitoring has shown that intraoperative strokes occur during the periods when emboli are most frequently seen on TCD [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/41\">",
"       41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Despite these findings, it is controversial whether TCD monitoring can be used to reduce the incidence of neurologic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Somatosensory evoked potentials &mdash; Somatosensory evoked potentials monitoring detects the onset and laterality of stroke during cardiac operations [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/41\">",
"       41",
"      </a>",
"      ]. However, its efficacy in minimizing the severity of an intraoperative stroke has not been demonstrated.",
"     </li>",
"     <li>",
"      S100 beta &mdash; The central nervous system protein S100 beta is released into the peripheral blood following neurologic injury. Early studies suggested that measurement of the serum concentration of S100 beta could be predictive of neurologic injury during cardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. However, subsequent reports determined that intraoperative measurements of S100 beta are often falsely elevated due to cross reactivity of the assay antibody with unidentified proteins from other sources [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. As a result, S100 beta is not a useful marker of intraoperative neurologic complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pharmacologic neuroprotection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic interventions may decrease the incidence or severity of neurologic complications associated with cardiac operations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a post hoc analysis of over 5000 CABG patients of whom 54 percent were on preoperative statins, there was no significant difference in the rate of the combined primary endpoint of stroke and encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/46\">",
"     46",
"    </a>",
"    ]. The results of this study should not influence the decision to use preoperative statins, as most patients referred for coronary artery bypass surgery (CABG) have a guideline recommended indication for long-term statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barbiturates decrease cerebral oxygen demands and theoretically could provide some protection in the setting of incomplete ischemia. Other agents that reduce reperfusion injury, cerebral edema, or the consequences of the inflammatory reaction to tissue injury may also be beneficial.",
"   </p>",
"   <p>",
"    A clinical trial randomly assigned 192 patients undergoing open chamber cardiac procedures at 34&ordm;C to receive either sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    (to maintain a burst suppression pattern on EEG throughout the period of cardiopulmonary bypass) or standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/47\">",
"     47",
"    </a>",
"    ]. None of the thiopental patients suffered neuropsychiatric disturbances 10 days postoperatively, compared with 7.5 percent of the patients in the control group. However, treatment with thiopental is not used routinely because of the risk of intraoperative hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small randomized pilot trial in 32 patients examined the use of recombinant erythropoietin as a neuroprotectant during CABG surgery; the treatment appears safe, and there was a trend to benefit in neurocognitive outcomes that did not meet statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2168/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H823526835\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications are second only to heart failure as a cause of morbidity and mortality following cardiac surgery. However, few preventative measures have been shown to improve neurologic outcomes. The following interventions may reduce the risk of neurologic complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative evaluation reduces perioperative injuries by allowing formal identification and treatment of preexisting risk factors. Preoperative carotid duplex imaging should be considered in patients with an audible bruit, severe peripheral artery disease, or a previous stroke or transient ischemic attack. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      should be continued in the perioperative period, as the benefit from protection against thromboembolic events is greater than the risk of bleeding. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although no study has confirmed a stroke risk reduction from the use of beta blockers, they should be given, if possible, to prevent the development of atrial fibrillation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clear advantage to minimally invasive off-pump CABG (OP CABG) compared with conventional CABG has not been demonstrated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Minimally invasive surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal regulation of patient temperature, acid-base status, and blood pressure likely improves neurologic outcomes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardiopulmonary bypass'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/1\">",
"      Hogue CW Jr, Barzilai B, Pieper KS, et al. Sex differences in neurological outcomes and mortality after cardiac surgery: a society of thoracic surgery national database report. Circulation 2001; 103:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/2\">",
"      Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. N Engl J Med 1996; 335:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/3\">",
"      Aldea GS, Mokadam NA, Melford R Jr, et al. Changing volumes, risk profiles, and outcomes of coronary artery bypass grafting and percutaneous coronary interventions. Ann Thorac Surg 2009; 87:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/4\">",
"      Racz MJ, Hannan EL, Isom OW, et al. A comparison of short- and long-term outcomes after off-pump and on-pump coronary artery bypass graft surgery with sternotomy. J Am Coll Cardiol 2004; 43:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/5\">",
"      Royse AG, Royse CF. Epiaortic ultrasound assessment of the aorta in cardiac surgery. Best Pract Res Clin Anaesthesiol 2009; 23:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/6\">",
"      Cheung, AT, Stecker, MM. Neurologic complications of cardiac surgery. Prog Anaesthesiol 1998; 12:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/7\">",
"      Brener BJ, Brief DK, Alpert J, et al. The risk of stroke in patients with asymptomatic carotid stenosis undergoing cardiac surgery: a follow-up study. J Vasc Surg 1987; 5:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/8\">",
"      D'Agostino RS, Svensson LG, Neumann DJ, et al. Screening carotid ultrasonography and risk factors for stroke in coronary artery surgery patients. Ann Thorac Surg 1996; 62:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/9\">",
"      Bass A, Krupski WC, Dilley RB, Bernstein EF. Combined carotid endarterectomy and coronary artery revascularization: a sobering review. Isr J Med Sci 1992; 28:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/10\">",
"      Hogue CW Jr, Murphy SF, Schechtman KB, D&aacute;vila-Rom&aacute;n VG. Risk factors for early or delayed stroke after cardiac surgery. Circulation 1999; 100:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/11\">",
"      Fukuda I, Gomi S, Watanabe K, Seita J. Carotid and aortic screening for coronary artery bypass grafting. Ann Thorac Surg 2000; 70:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/12\">",
"      Durand DJ, Perler BA, Roseborough GS, et al. Mandatory versus selective preoperative carotid screening: a retrospective analysis. Ann Thorac Surg 2004; 78:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/13\">",
"      Sedrakyan A, Wu AW, Parashar A, et al. Off-pump surgery is associated with reduced occurrence of stroke and other morbidity as compared with traditional coronary artery bypass grafting: a meta-analysis of systematically reviewed trials. Stroke 2006; 37:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/14\">",
"      Wijeysundera DN, Beattie WS, Djaiani G, et al. Off-pump coronary artery surgery for reducing mortality and morbidity: meta-analysis of randomized and observational studies. J Am Coll Cardiol 2005; 46:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/15\">",
"      Cheng DC, Bainbridge D, Martin JE, et al. Does off-pump coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with conventional coronary artery bypass? A meta-analysis of randomized trials. Anesthesiology 2005; 102:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/16\">",
"      Van Dijk D, Jansen EW, Hijman R, et al. Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery: a randomized trial. JAMA 2002; 287:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/17\">",
"      van Dijk D, Spoor M, Hijman R, et al. Cognitive and cardiac outcomes 5 years after off-pump vs on-pump coronary artery bypass graft surgery. JAMA 2007; 297:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/18\">",
"      Jensen BO, Hughes P, Rasmussen LS, et al. Cognitive outcomes in elderly high-risk patients after off-pump versus conventional coronary artery bypass grafting: a randomized trial. Circulation 2006; 113:2790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/19\">",
"      Ascione R, Ghosh A, Reeves BC, et al. Retinal and cerebral microembolization during coronary artery bypass surgery: a randomized, controlled trial. Circulation 2005; 112:3833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/20\">",
"      Shroyer AL, Grover FL, Hattler B, et al. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med 2009; 361:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/21\">",
"      Zamvar V, Williams D, Hall J, et al. Assessment of neurocognitive impairment after off-pump and on-pump techniques for coronary artery bypass graft surgery: prospective randomised controlled trial. BMJ 2002; 325:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/22\">",
"      Sharony R, Bizekis CS, Kanchuger M, et al. Off-pump coronary artery bypass grafting reduces mortality and stroke in patients with atheromatous aortas: a case control study. Circulation 2003; 108 Suppl 1:II15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/23\">",
"      Karthik S, Musleh G, Grayson AD, et al. Coronary surgery in patients with peripheral vascular disease: effect of avoiding cardiopulmonary bypass. Ann Thorac Surg 2004; 77:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/24\">",
"      Greeley WJ, Kern FH, Ungerleider RM, et al. The effect of hypothermic cardiopulmonary bypass and total circulatory arrest on cerebral metabolism in neonates, infants, and children. J Thorac Cardiovasc Surg 1991; 101:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/25\">",
"      Randomised trial of normothermic versus hypothermic coronary bypass surgery. The Warm Heart Investigators. Lancet 1994; 343:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/26\">",
"      Martin TD, Craver JM, Gott JP, et al. Prospective, randomized trial of retrograde warm blood cardioplegia: myocardial benefit and neurologic threat. Ann Thorac Surg 1994; 57:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/27\">",
"      Grocott HP, Mackensen GB, Grigore AM, et al. Postoperative hyperthermia is associated with cognitive dysfunction after coronary artery bypass graft surgery. Stroke 2002; 33:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/28\">",
"      Patel RL, Turtle MR, Chambers DJ, et al. Alpha-stat acid-base regulation during cardiopulmonary bypass improves neuropsychologic outcome in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1996; 111:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/29\">",
"      Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch Neurol 1998; 55:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/30\">",
"      Gottesman RF, Hillis AE, Grega MA, et al. Early postoperative cognitive dysfunction and blood pressure during coronary artery bypass graft operation. Arch Neurol 2007; 64:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/31\">",
"      Gold JP, Charlson ME, Williams-Russo P, et al. Improvement of outcomes after coronary artery bypass. A randomized trial comparing intraoperative high versus low mean arterial pressure. J Thorac Cardiovasc Surg 1995; 110:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/32\">",
"      Edmonds HL Jr, Rodriguez RA, Audenaert SM, et al. The role of neuromonitoring in cardiovascular surgery. J Cardiothorac Vasc Anesth 1996; 10:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/33\">",
"      Stern A, Tunick PA, Culliford AT, et al. Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy. Am Heart J 1999; 138:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/34\">",
"      Davila-Roman VG, Barzilai B, Wareing TH, et al. Intraoperative ultrasonographic evaluation of the ascending aorta in 100 consecutive patients undergoing cardiac surgery. Circulation 1991; 84:III47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/35\">",
"      Wareing TH, Davila-Roman VG, Barzilai B, et al. Management of the severely atherosclerotic ascending aorta during cardiac operations. A strategy for detection and treatment. J Thorac Cardiovasc Surg 1992; 103:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/36\">",
"      Ura M, Sakata R, Nakayama Y, Goto T. Ultrasonographic demonstration of manipulation-related aortic injuries after cardiac surgery. J Am Coll Cardiol 2000; 35:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/37\">",
"      Levy WJ. Monitoring of the electroencephalogram during cardiopulmonary bypass. Know when to say when. Anesthesiology 1992; 76:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/38\">",
"      Fode NC, Sundt TM Jr, Robertson JT, et al. Multicenter retrospective review of results and complications of carotid endarterectomy in 1981. Stroke 1986; 17:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/39\">",
"      Clark RE, Brillman J, Davis DA, et al. Microemboli during coronary artery bypass grafting. Genesis and effect on outcome. J Thorac Cardiovasc Surg 1995; 109:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/40\">",
"      Barbut D, Hinton RB, Szatrowski TP, et al. Cerebral emboli detected during bypass surgery are associated with clamp removal. Stroke 1994; 25:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/41\">",
"      Stecker MM, Cheung AT, Patterson T, et al. Detection of stroke during cardiac operations with somatosensory evoked responses. J Thorac Cardiovasc Surg 1996; 112:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/42\">",
"      Johnsson P, Lundqvist C, Lindgren A, et al. Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood. J Cardiothorac Vasc Anesth 1995; 9:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/43\">",
"      Grocott HP, Arrowsmith JE. Serum S100 protein as a marker of cerebral damage during cardiac surgery. Br J Anaesth 2001; 86:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/44\">",
"      J&ouml;nsson H, Johnsson P, Alling C, et al. S100beta after coronary artery surgery: release pattern, source of contamination, and relation to neuropsychological outcome. Ann Thorac Surg 1999; 68:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/45\">",
"      Fazio V, Bhudia SK, Marchi N, et al. Peripheral detection of S100beta during cardiothoracic surgery: what are we really measuring? Ann Thorac Surg 2004; 78:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/46\">",
"      Koenig MA, Grega MA, Bailey MM, et al. Statin use and neurologic morbidity after coronary artery bypass grafting: A cohort study. Neurology 2009; 73:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/47\">",
"      Nussmeier NA, Arlund C, Slogoff S. Neuropsychiatric complications after cardiopulmonary bypass: cerebral protection by a barbiturate. Anesthesiology 1986; 64:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2168/abstract/48\">",
"      Haljan G, Maitland A, Buchan A, et al. The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial. Stroke 2009; 40:2769.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1564 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2168=[""].join("\n");
var outline_f2_7_2168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H823526835\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REDUCING NEUROLOGIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Minimally invasive surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiopulmonary bypass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bypass temperature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acid-base status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intraoperative monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - TEE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - EEG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pharmacologic neuroprotection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H823526835\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1564|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/21/14685\" title=\"figure 1\">",
"      Impact of age on adverse cerebral outcomes after CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1564|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/33/16925\" title=\"table 1\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6617?source=related_link\">",
"      Coronary artery bypass grafting in patients with cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16922?source=related_link\">",
"      Management of asymptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=related_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_7_2169="Epidemiology and transmission of hepatitis C virus infection";
var content_f2_7_2169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and transmission of hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2169/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2169/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2169/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2169/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/7/2169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hepatitis C virus (HCV) infection is one of the most common chronic liver disease and accounts for 8000 to 13,000 deaths each year. The majority of liver transplants performed in the United States are for chronic HCV.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology and transmission of HCV. Screening for HCV, the approach to patients with acute HCV, and the clinical features, diagnosis, natural history, and management of patients with chronic HCV are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"       \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"       \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"       \"Overview of the management of chronic hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"       \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=see_link\">",
"       \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"       \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=see_link\">",
"       \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link\">",
"       \"Investigational therapies for hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link\">",
"       \"Liver transplantation for hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, it was estimated that in 2005, more than 185 million people had hepatitis C virus (HCV) antibodies (prevalence of 2.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Areas with high prevalences (&gt;3.5 percent) included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central and East Asia",
"     </li>",
"     <li>",
"      North Africa",
"     </li>",
"     <li>",
"      The Middle East",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moderate prevalences (1.5 to 3.5 percent) were noted in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      South and Southeast Asia",
"     </li>",
"     <li>",
"      Sub-Saharan Africa",
"     </li>",
"     <li>",
"      Andean, Central, and Southern Latin America",
"     </li>",
"     <li>",
"      The Caribbean",
"     </li>",
"     <li>",
"      Oceania",
"     </li>",
"     <li>",
"      Australasia (Australia, New Zealand, New Guinea, and neighboring Pacific islands)",
"     </li>",
"     <li>",
"      Western, Central, and Eastern Europe",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low prevalences (&lt;1.5 percent) were noted in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Asia Pacific",
"     </li>",
"     <li>",
"      Tropical Latin America",
"     </li>",
"     <li>",
"      North America.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Centers for Disease Control estimates that the number of new cases of acute HCV infection in the United States has fallen from approximately 230,000 per year in the 1980s to its current level of about 17,000 cases per year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/2\">",
"     2",
"    </a>",
"    ]. The overall incidence in 2010 was estimated to be 0.3 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The decline relates primarily to reduced infections in injection drug users, a probable consequence of changes in injection practices motivated by a concern for HIV risk. The number of cases of transfusion-associated acute hepatitis C decreased significantly after 1985 and has been reduced almost to zero [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, transfusion-associated hepatitis has had little impact on the recent change in the incidence of HCV infection (",
"    <a class=\"graphic graphic_figure graphicRef54694 graphicRef80407 graphicRef53650 \" href=\"UTD.htm?25/4/25664\">",
"     figure 1A-C",
"    </a>",
"    ). Overall, approximately 75 percent of patients with chronic HCV in the United States were born between 1945 and 1965, with a prevalence of 3.25 percent, leading to a 2012 recommendation by the Centers for Disease Control and Prevention to routinely screen all patients in this birth cohort for HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\", section on 'Who should be tested'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the overall decline in HCV infection rates, HCV infection rates among young adults may be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Data reported to the Massachusetts Department of Public Health between 2002 and 2009 found an increase in the rate of newly reported HCV infection among patients age 15 to 24 years, from 65 cases per 100,000 in 2002 to 113 cases per 100,000 in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/6\">",
"     6",
"    </a>",
"    ]. The majority of patients in this age group were white (78 percent) with an equal male:female distribution. Intravenous drug use was the most common risk factor (72 percent). In addition, it is estimated that 16 to 41 percent of adult prison inmates have serologic evidence of HCV infection, and that 12 to 35 percent are chronically infected [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the 2006 National Health and Nutrition Examination Survey (NHANES) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/9\">",
"     9",
"    </a>",
"    ], the prevalence of antibodies to HCV (anti-HCV) in the United States is approximately 1.6 percent (equating to about 4.1 million anti-HCV positive persons), while the prevalence of positive HCV RNA is approximately 1.3 percent (or about 3.2 million persons who are HCV RNA-positive). The peak prevalence is observed among persons born between 1945 and 1964. The strongest risk factor for infection is a history of injection drug use.",
"   </p>",
"   <p>",
"    NHANES found that anti-HCV antibodies were more common in non-Hispanic black and Mexican American people, those with low family income, and in those with a lifetime history of &ge;20 sexual partners. HCV RNA positive participants were more likely to be men, have an abnormal serum ALT, and to report heavier alcohol intake compared with those who were HCV RNA negative. Three characteristics (an abnormal serum ALT, any history of injection drug use, and a history of a blood transfusion before 1992) identified 85 percent of HCV RNA positive participants between the ages of 20 to 59 years, suggesting that these criteria are useful for identifying patients for whom screening for HCV can be considered.",
"   </p>",
"   <p>",
"    Most cases of acute hepatitis C are anicteric and asymptomatic, with fewer than 25 percent being clinically apparent. Fulminant hepatitis C is rare. Nevertheless, the long-term liability of acute hepatitis C is significant due to the high rate of chronic infection (HCV-RNA positive in 55 to 85 percent of cases) and chronic hepatitis (elevated serum ALT concentration in 60 to 80 percent of patients with chronic infection). Approximately 20 to 30 percent of those chronically infected will develop cirrhosis, and a proportion of those patients will develop hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The annual costs related to hepatitis C in the United States were estimated in a study that aggregated data from multiple data sets collected by the National Center for Health Statistics, the Health Care Financing Administration, and other government bureaus and private firms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/14\">",
"     14",
"    </a>",
"    ]. In 1997, the cost of hepatitis C was approximately $5.46 billion, the bulk of which (92 percent) was due to chronic liver disease; the remaining costs were related to hepatocellular carcinoma. This figure is similar to the annual costs of asthma. The estimate was considered to be conservative since it did not include costs related to pain and suffering and the value of care provided by family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients infected with HCV in the United States and Europe acquired the disease through intravenous drug use or blood transfusion, the latter of which has become rare since routine testing of the blood supply for HCV was begun in 1990. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Blood transfusion'",
"    </a>",
"    below.) Other types of parenteral exposure are important in specific regions in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No identifiable risk factors for HCV infection during the previous six months can be identified in up to 44 percent of cases with new infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/16\">",
"     16",
"    </a>",
"    ]. This rate is similar to that seen with acute hepatitis A or B infection. However, after careful questioning, most of these patients give a past history of high-risk behavior (such as injection drug use), and many are from low socioeconomic strata, which is known to be associated with a greater risk of hepatitis. Some of these risk factors were elucidated in a case control study from the United States involving 2316 HCV positive blood donors in whom the following HCV risk factors were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravenous drug use &ndash; odds ratio 49.6",
"     </li>",
"     <li>",
"      Blood transfusion &ndash; odds ratio 10.9",
"     </li>",
"     <li>",
"      Sex with an intravenous drug user &ndash; odds ratio 6.3",
"     </li>",
"     <li>",
"      Having been in jail more than three days &ndash; odds ratio 2.9",
"     </li>",
"     <li>",
"      Religious scarification &ndash; odds ratio 2.8",
"     </li>",
"     <li>",
"      Having been struck or cut with a bloody object &ndash; odds ratio 2.1",
"     </li>",
"     <li>",
"      Pierced ears or body parts &ndash; odds ratio 2.0",
"     </li>",
"     <li>",
"      Immunoglobulin injection &ndash; odds ratio 1.6",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Illicit drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral exposure to the hepatitis C virus is the most efficient means of transmission. Thus, it is not surprising that injection drug use with shared needles or other paraphernalia has been the most common identifiable source of acute HCV infection in the United States. Current estimates suggest that over 60 percent of newly acquired infections occur in individuals who have injected illegal drugs during the six months prior to disease onset (",
"    <a class=\"graphic graphic_figure graphicRef74500 \" href=\"UTD.htm?26/25/27039\">",
"     figure 2",
"    </a>",
"    ) and that up to 77 percent of injecting drug users are anti-HCV positive [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficiency of transmission via this route is evidenced by the high rate of anti-HCV antibodies observed in short-term injectors. In one report, analysis of blood from 716 injection drug users found that the seroprevalence of HCV was 64.7 percent among those who had injected for one year or less [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/19\">",
"     19",
"    </a>",
"    ]. By comparison, the seroprevalences of hepatitis B virus, HIV, and HTLV were 49.8, 13.9, and 0.5 percent, respectively. HCV infection also has been associated with a history of intranasal cocaine use, presumably due to blood on shared straws [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood transfusion was a major risk factor for acute infection in the past, with more than 10 percent of transfusion recipients acquiring infection in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/21\">",
"     21",
"    </a>",
"    ]. The screening of blood donors for historical risk factors, serologic evidence of hepatitis B infection (HBsAg and anti-HBc), and elevated serum ALT caused a striking reduction in the rates of non-A, non-B post-transfusion hepatitis, even before HCV was identified (",
"    <a class=\"graphic graphic_figure graphicRef53650 \" href=\"UTD.htm?1/3/1086\">",
"     figure 1C",
"    </a>",
"    ). The subsequent initiation of donor screening for anti-HCV antibodies in 1990 has nearly eliminated the risk of posttransfusion acute HCV infection. The estimated risk is now less than one in a million per unit transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the spring of 1999, another blood donor HCV testing technology, nucleic acid testing (NAT), was introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/23\">",
"     23",
"    </a>",
"    ]. It is anticipated that this technology, which detects HCV genetic material rather than later-appearing antibodies, will further decrease the risk of transfusion-transmitted HCV by 5- to 10-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This continuing decline in risk of posttransfusion HCV explains the observation that a history of blood product transfusion is much more common in patients presenting with chronic HCV (remote infection) than with acute infection.",
"   </p>",
"   <p>",
"    Multiply transfused patients, including those with thalassemia or hemophilia, have been at particularly high risk of developing hepatitis C. The prevalence of anti-HCV in hemophiliacs who regularly received concentrates of clotting factors before adequate procedures were used to inactivate viruses (eg, heat inactivation or pasteurization) was 84 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/26\">",
"     26",
"    </a>",
"    ]. Since the use of treated or recombinant clotting factors has become routine, new cases of hepatitis C infection have become uncommon in these patients. The continued high prevalence of anti-HCV in this population is due to past exposure to untreated concentrates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Health care workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to HCV in healthcare workers are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial transmission of HCV has been documented in several health care settings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. A study from Spain suggested that hospitalization itself was an important cause of acute HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/28\">",
"     28",
"    </a>",
"    ]. Hospitalization was believed to account for 73 of 109 cases (67 percent) of acute HCV cases documented in 18 Spanish hospitals, which accounted for more cases than intravenous drug use (8 percent), needle stick injury (6 percent), and sexual contact (5 percent). Of these patients, 33 had undergone surgery, 24 were admitted to a medical emergency unit or ward, and the remaining had undergone diagnostic or therapeutic procedures.",
"   </p>",
"   <p>",
"    Whether hospitalization poses a similar risk in other countries is unclear. It is possible that transmission during hospitalization was due to unsafe medication injection practices [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/29\">",
"     29",
"    </a>",
"    ]. Policies in some countries (including the United States) have specified protocols to prevent such transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant recipients who receive organs from HCV-positive donors have a high risk of acquiring HCV infection and liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Some studies have shown nearly universal transmission; in one report, 75 percent of the 29 recipients of organs (19 kidneys, 6 hearts, 4 livers) from 13 anti-HCV positive donors became anti-HCV or HCV-RNA positive [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/31\">",
"     31",
"    </a>",
"    ]. Others have not found quite as strong an association; only 13 of 46 (29 percent) recipients of RIBA-positive donors developed posttransplant liver disease in a second series, although HCV-RNA was not checked [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the latter study, concern over the risk of HCV transmission is great. Most procurement organizations and transplant centers have now developed policies for screening and selective utilization of organs from anti-HCV positive donors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sexual or household contact",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficiency of HCV transmission by sexual or household contact is low. The majority of the data does not support transmission to nonsexual partners [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little doubt that sexual transmission can occur, although the risk appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. The seroprevalence of anti-HCV is increased among promiscuous heterosexuals and male homosexuals, groups which serve as an epidemiologic barometer of sexual transmission risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. The risk appears to be similar among partners of heterosexual or homosexual index cases who are not infected with HIV.",
"   </p>",
"   <p>",
"    The risk of transmission of HCV infection between monogamous sexual partners has been difficult to demonstrate in prospective studies. One of the largest studies to examine rates of transmission in detail (reported in preliminary form) focused on 500 monogamous, heterosexual couples who had had sexual contact for a median of 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/37\">",
"     37",
"    </a>",
"    ]. Only 17 percent reported regular or frequent use of condoms. A total of 20 partners (4 percent) had HCV antibodies. However, 40 percent of these patients had discordant",
"    <span class=\"nowrap\">",
"     genotypes/serotypes",
"    </span>",
"    suggesting that they had acquired HCV through other routes of transmission. In addition, of those with concordant genotypes, phylogenetic evaluation found that the viral isolates from both members of the couple were highly related in three of the couples (0.6 percent of the total population studied), consistent with transmission of the virus within the couple. The overall incidence of HCV transmission by sex was estimated to be 0.07 percent per year.",
"   </p>",
"   <p>",
"    Another large, prospective study included 895 monogamous, heterosexual partners of HCV infected individuals who were followed for 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/40\">",
"     40",
"    </a>",
"    ]. The average weekly rate of sexual intercourse was 1.8. All couples denied practicing anal intercourse, having sex during menstruation, or use of condoms. During follow-up, three patients developed HCV infection; however, molecular analysis showed that none had acquired it from their spouse.",
"   </p>",
"   <p>",
"    Other, retrospective studies estimate the likelihood of transmission under these circumstances to be approximately 0.1 percent annually [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/36\">",
"     36",
"    </a>",
"    ]. A potential mechanism of nonsexual transmission in these instances is mucosal exposure to infectious blood or to body fluids containing blood, or inapparent percutaneous exposure through personal hygiene items (eg, shared razors or toothbrushes). In many situations, it is difficult to rule out the possibility that transmission resulted from common exposure to risk factors other than sexual exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of sexual transmission may be higher if the index case is coinfected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/41\">",
"     41",
"    </a>",
"    ]. In one report, for example, the anti-HCV prevalence in stable heterosexual partners of",
"    <span class=\"nowrap\">",
"     HCV-positive/HIV-positive",
"    </span>",
"    index cases was 2.2 times higher than in stable heterosexual partners of index cases reactive for anti-HCV only (9.2 versus 4.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/43\">",
"     43",
"    </a>",
"    ]. Other factors associated with anti-HCV positivity included greater numbers of sexual partners, history of sexually transmitted diseases, and failure to use a condom. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with acute or chronic HCV infection should be advised that transmission to sexual or household contacts is a possibility, although the risk is relatively low. It is likely that the use of condoms will lower the risk of sexual transmission further, similar to the case with hepatitis B virus and HIV. However, the United States Public Health Service and a consensus statement issued by the National Institutes of Health have not recommended barrier precautions between stable monogamous sexual partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Perinatal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal transmission of HCV occurs at the time of birth in about 5 percent of infants born to anti-HCV positive women [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/45\">",
"     45",
"    </a>",
"    ]. The risk of infection is approximately twofold higher in infants born to women coinfected with HCV and HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/46\">",
"     46",
"    </a>",
"    ]. Transmission occurs almost exclusively from mothers who are HCV-RNA positive (as opposed to those who are anti-HCV positive but HCV-RNA negative) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/47\">",
"     47",
"    </a>",
"    ]. The risk of transmission is, like HIV, in part related to the level of viremia at the time of birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of pregnant women or unusual precautions to reduce the risk of transmission is not recommended at this time. Early diagnosis of infection in newborns requires HCV-RNA testing since anti-HCV antibodies are passively transferred from the mother. There is no evidence that breastfeeding is a risk for infection among infants born to HCV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of HCV infection among patients on dialysis has steadily declined in recent years. Among member nations in the European Dialysis and Transplant Association, for example, the prevalence of anti-HCV declined from 21 percent in 1992 to 17.7 percent in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/49\">",
"     49",
"    </a>",
"    ]. Nonetheless, the 0.4 to 15 percent incidence of anti-HCV positivity in hemodialysis units continues to be a cause for concern. A number of risk factors have been identified for HCV infection among dialysis patients, including blood transfusions, the duration of end-stage renal disease (and dialysis), the type of dialysis (risk is highest with in-hospital hemodialysis and lowest with peritoneal dialysis), and the prevalence of HCV infection in the dialysis unit.",
"   </p>",
"   <p>",
"    Unresolved debate continues as to whether transmission of HCV in hemodialysis units may be affected by routine testing for anti-HCV antibodies, patient isolation, use of dedicated machines, and a ban on dialyzer reuse. The Centers for Disease Control and Prevention in the United States (CDC) does",
"    <strong>",
"     not",
"    </strong>",
"    recommend dedicated machines, patient isolation, or a ban on reuse in hemodialysis patients with HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/50\">",
"     50",
"    </a>",
"    ]. However, strict adherence to \"universal precautions,\" careful attention to hygiene, and strict sterilization of dialysis machines is recommended. Conventional cleansing and sterilization appear to be adequate to inactivate the virus. Unfortunately, eliminating the spread of HCV infection in hemodialysis units may require the development of treatments to eradicate the virus or vaccines to prevent infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31114?source=see_link\">",
"     \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare sources of transmission of HCV include contaminated equipment used during the performance of procedures and other breakdowns of infection control procedures or aseptic techniques leading to person-to-person transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/50-56\">",
"     50-56",
"    </a>",
"    ]. For example, an outbreak of acute hepatitis C was identified in three hospitalized patients who received saline flushes from a multidose saline vial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/52\">",
"     52",
"    </a>",
"    ]. Another outbreak of six cases of hepatis C (along with six cases of hepatitis B) was linked to the inappropriate reuse of syringes and single-patient-use vials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    by a single anesthesiologist [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Procedures involved in traditional medicine, folk medicine (eg, scarification, cupping), tattooing, body piercing, and commercial barbering may also transmit HCV on rare occasions. Hospitalization for longer than 10 days in a liver unit was associated with an increased risk of HCV transmission from infected patients (typically roommates) in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surprisingly high rates of HCV infection (approximately 30 percent) have been found in patients with alcohol abuse, even in the absence of other risk factors for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. HCV may accelerate the liver injury in patients who drink heavily [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/62\">",
"     62",
"    </a>",
"    ], alcohol use appears to decrease the efficacy of interferon therapy for HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/63\">",
"     63",
"    </a>",
"    ], and patients with alcohol and HCV-induced liver injury have a greater risk for hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9496?source=see_link\">",
"     \"Hepatitis C and alcohol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tattooing and body piercing have the potential to transmit HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2169/abstract/66\">",
"     66",
"    </a>",
"    ]. However, the extent to which they contribute to the disease burden of HCV is uncertain. There are no clear cut data in the United States indicating that individuals with exposure to tattooing or body piercing alone are at increased risk for acquiring hepatitis C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of antibodies to hepatitis C virus (anti-HCV) in the United States is approximately 1.6 percent (equating to about 4.1 million anti-HCV positive persons), while the prevalence of positive HCV RNA is approximately 1.3 percent (or about 3.2 million persons who are HCV RNA-positive). The peak prevalence is observed among persons born between 1945 and 1964. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following acute hepatitis C infection, 80 to 100 percent of patients will develop chronic infection, and 60 to 80 percent will develop chronic hepatitis (elevated ALT). Approximately 20 to 30 percent of patients who are chronically infected will develop cirrhosis, and a proportion of those patients will develop hepatocellular carcinoma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients infected with HCV in the United States and Europe acquired the disease through intravenous drug use or blood transfusion, the latter of which has become rare since routine testing of the blood supply for HCV began in 1990. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple risk factors for the transmission of HCV have been identified. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous drug use - odds ratio 49.6",
"     </li>",
"     <li>",
"      Blood transfusion - odds ratio 10.9",
"     </li>",
"     <li>",
"      Sex with an intravenous drug user - odds ratio 6.3",
"     </li>",
"     <li>",
"      Having been in jail more than three days - odds ratio 2.9",
"     </li>",
"     <li>",
"      Religious scarification - odds ratio 2.8",
"     </li>",
"     <li>",
"      Having been struck or cut with a bloody object - odds ratio 2.1",
"     </li>",
"     <li>",
"      Pierced ears or body parts - odds ratio 2.0",
"     </li>",
"     <li>",
"      Immunoglobulin injection - odds ratio 1.6",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/1\">",
"      Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/2\">",
"      Wasley A, Grytdal S, Gallagher K, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/hepatitis/Statistics/2010Surveillance/index.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/4\">",
"      Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S.",
"     </a>",
"    </li>",
"    <li>",
"     Smith BD, Patel N, Beckett GA, et al. Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999&ndash;2008 [Abstract]. American Association for the Study of Liver Disease; San Francisco, CA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users--new York, November 2004-April 2007. MMWR Morb Mortal Wkly Rep 2008; 57:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/8\">",
"      Weinbaum C, Lyerla R, Margolis HS, Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/9\">",
"      Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/10\">",
"      Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/11\">",
"      Vogt M, Lang T, Fr&ouml;sner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/12\">",
"      Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/13\">",
"      Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997; 26:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/14\">",
"      Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med 2001; 161:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/15\">",
"      Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/16\">",
"      Alter MJ, Gerety RJ, Smallwood LA, et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982; 145:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/17\">",
"      Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/18\">",
"      Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/19\">",
"      Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/20\">",
"      Aaron S, McMahon JM, Milano D, et al. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis 2008; 47:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/21\">",
"      Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/22\">",
"      Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol 2003; 10:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/23\">",
"      Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002; 42:1230.",
"     </a>",
"    </li>",
"    <li>",
"     America's Blood Centers Newsletter 1999; 13:2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/25\">",
"      Sch&uuml;ttler CG, Caspari G, Jursch CA, et al. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 2000; 355:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/26\">",
"      Mauser-Bunschoten EP, Bresters D, van Drimmelen AA, et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995; 45:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/27\">",
"      Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/28\">",
"      Mart&iacute;nez-Bauer E, Forns X, Armelles M, et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 2008; 48:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/29\">",
"      Alter MJ. Healthcare should not be a vehicle for transmission of hepatitis C virus. J Hepatol 2008; 48:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/30\">",
"      Perz JF, Grytdal S, Beck S, et al. Case-control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections? Hepatology 2013; 57:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/31\">",
"      Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/32\">",
"      Pfau PR, Rho R, DeNofrio D, et al. Hepatitis C transmission and infection by orthotopic heart transplantation. J Heart Lung Transplant 2000; 19:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/33\">",
"      Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/34\">",
"      Kiberd BA. Should hepatitis C-infected kidneys be transplanted in the United States? Transplantation 1994; 57:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/35\">",
"      Everhart JE, Di Bisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990; 112:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/36\">",
"      Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology 1997; 26:66S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/37\">",
"      Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. Hepatology 2013; 57:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/38\">",
"      Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989; 262:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/39\">",
"      Stroffolini T, Lorenzoni U, Menniti-Ippolito F, et al. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol 2001; 96:3138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/40\">",
"      Vandelli C, Renzo F, Roman&ograve; L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004; 99:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/41\">",
"      Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010; 52:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/42\">",
"      Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/43\">",
"      Lissen E, Alter HJ, Abad MA, et al. Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis 1993; 12:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/44\">",
"      Zylberberg H, Thiers V, Lagorce D, et al. Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut 1999; 45:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/45\">",
"      Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/46\">",
"      Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995; 345:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/47\">",
"      Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/48\">",
"      Lin HH, Kao JH, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995; 126:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/49\">",
"      Geerlings W, Tufveson G, Ehrich JH, et al. Report on management of renal failure in Europe, XXIII. Nephrol Dial Transplant 1994; 9 Suppl 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/50\">",
"      Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of dialysis-associated diseases in the United States, 1989. ASAIO Trans 1991; 37:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/51\">",
"      Stark K, H&auml;nel M, Berg T, Schreier E. Nosocomial transmission of hepatitis C virus from an anesthesiologist to three patients--epidemiologic and molecular evidence. Arch Virol 2006; 151:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/52\">",
"      Krause G, Trepka MJ, Whisenhunt RS, et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol 2003; 24:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/53\">",
"      S&aacute;nchez-Tapias JM. Nosocomial transmission of hepatitis C virus. J Hepatol 1999; 31 Suppl 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/54\">",
"      Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009; 150:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/55\">",
"      Widell A, Christensson B, Wiebe T, et al. Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service. Ann Intern Med 1999; 130:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/56\">",
"      Massari M, Petrosillo N, Ippolito G, et al. Transmission of hepatitis C virus in a gynecological surgery setting. J Clin Microbiol 2001; 39:2860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/57\">",
"      Gutelius B, Perz JF, Parker MM, et al. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology 2010; 139:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/58\">",
"      Forns X, Mart&iacute;nez-Bauer E, Feliu A, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 2005; 41:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/59\">",
"      Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore) 2001; 80:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/60\">",
"      Par&eacute;s A, Barrera JM, Caballer&iacute;a J, et al. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology 1990; 12:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/61\">",
"      Mendenhall CL, Moritz T, Rouster S, et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol 1993; 88:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/62\">",
"      Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/63\">",
"      Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/64\">",
"      Nalpas B, Driss F, Pol S, et al. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991; 12:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/65\">",
"      Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2169/abstract/66\">",
"      Bronowicki JP, Venard V, Bott&eacute; C, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med 1997; 337:237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3675 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-02B1BD5894-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2169=[""].join("\n");
var outline_f2_7_2169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Illicit drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Health care workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sexual or household contact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Perinatal transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3675|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/55/1918\" title=\"figure 1A\">",
"      Incidence HCV by risk factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/26/32173\" title=\"figure 1B\">",
"      Decline HCV incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/3/1086\" title=\"figure 1C\">",
"      Decline post transfusion HCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/25/27039\" title=\"figure 2\">",
"      Risk factors acute hepatitis C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9496?source=related_link\">",
"      Hepatitis C and alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31114?source=related_link\">",
"      Hepatitis C virus infection in patients on maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=related_link\">",
"      Vertical transmission of hepatitis C virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_7_2170="Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)";
var content_f2_7_2170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2170/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2170/contributors\">",
"     Nelly Pitteloud, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2170/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2170/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2170/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2170/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/7/2170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/7/2170/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/7/2170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital gonadotropin-releasing hormone (GnRH) deficiency refers to the functional absence of GnRH secretion from hypothalamic hypophysiotropic neurons or a defect in its action at the level of the gonadotrope in the case of mutations in the GnRH receptor. This defect results in idiopathic hypogonadotropic (secondary) hypogonadism (IHH) and is its most common cause. Other rare causes of IHH include mutations in the beta subunit of luteinizing (LH) and follicle stimulating hormones (FSH) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital GnRH deficiency is differentiated from primary gonadal failure by the demonstration of low serum concentrations of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in the setting of castrate levels of gonadal steroids. The diagnosis is presumptive, however, and can only be confirmed by normal radiologic studies of the hypothalamic-pituitary region. Testing of other anterior pituitary endocrine function should also be undertaken to assure that the defect in gonadotropin secretion is isolated. The major diagnostic problem is distinguishing this disorder from constitutional delay of puberty prior to age 18.",
"   </p>",
"   <p>",
"    Congenital GnRH deficiency will be discussed here. Other causes of hypogonadotropic hypogonadism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of endogenous GnRH secretion in patients with congenital GnRH deficiency cannot be proven by direct assay but can be reasonably inferred by two findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The complete lack of any endogenous GnRH-induced LH pulses during frequent blood sampling (",
"      <a class=\"graphic graphic_figure graphicRef56592 \" href=\"UTD.htm?26/59/27582\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The nearly universal response of serum LH to exogenous GnRH administered in a pulsatile regimen to mimic endogenous GnRH secretion (GnRH dose and frequency based upon a previous study of LH secretion in normal men) (",
"      <a class=\"graphic graphic_figure graphicRef55090 \" href=\"UTD.htm?16/9/16542\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/5\">",
"       5",
"      </a>",
"      ]. This responsiveness demonstrates the integrity of the gonadotrophs and the gonads in these patients. In contrast, patients with hypogonadism caused by inactivating mutations of the GnRH receptor can have a poor response to pulsatile GnRH administration [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H372820011\">",
"       'GnRH receptor mutations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372819954\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital GnRH deficiency (with or without anosmia) can be inherited as an autosomal dominant, autosomal recessive, or X-linked condition. Increasingly, however, oligogenic inheritance is being appreciated that is manifested by incomplete penetrance and variable expressivity within families sharing at least one mutation in a gene recognized to be critical for GnRH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than two-thirds of cases appear at first examination to be sporadic. However, the familial nature of many cases becomes apparent only upon extensive questioning of the proband and other family members. Critical clues, such as anosmia, the absence of menstrual periods, a family history of delayed puberty, or presence of skeletal abnormalities often are not even known by close family members. To date, several genes have been implicated in the etiology of congenital GnRH deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372819961\">",
"    <span class=\"h2\">",
"     KAL1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of the impaired secretion of GnRH in some cases has been described in the X-linked form of congenital GnRH deficiency: impaired migration of GnRH neurons to the ventral hypothalamus during embryogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Studies in both mice and humans have demonstrated that, unlike other hypothalamic neurosecretory neurons, GnRH neurons migrate from the olfactory placode outside the developing brain into the hypothalamus during fetal life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Proper migration of these neurons is dependent upon the correct expression of anosmin, a 680 amino acid neural cell adhesion molecule-like protein, which is the product of the KAL1 gene. In the rat, anosmin-1 promotes formation of collateral branches and enhances axonal branching of olfactory bulb neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/12\">",
"     12",
"    </a>",
"    ]. The gene for this protein (KALIG-1, or KAL), which is in the Xp 22.3 region of the X chromosome, is mutated in the X-linked form of GnRH deficiency (",
"    <a class=\"graphic graphic_figure graphicRef73697 \" href=\"UTD.htm?11/40/11918\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the KAL1 gene occur less often in sporadic cases (&lt;10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a series of 59 patients with Kallmann syndrome, of whom 21 were familial and 38 were sporadic, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmed mutations in the coding sequence of the KAL1 gene were seen in 14 and 11 percent of familial and sporadic cases respectively, suggesting that most cases are caused by mutations in autosomal genes (see below).",
"     </li>",
"     <li>",
"      Obligate female carriers in families with KAL1 mutations have no discernible phenotype.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the clinical phenotypes of idiopathic hypogonadotropic hypogonadism (IHH) subjects with KAL1 mutations are particularly severe with a high incidence of microphallus, cryptorchidism, and small testes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This subset of IHH patients also has the poorest response to therapy in terms of spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/20\">",
"     20",
"    </a>",
"    ]. Generally, patients with KAL1 mutations and their families appear as the most penetrant of the genes causing congenital GnRH deficiency, as well.",
"   </p>",
"   <p>",
"    X-linked KAL mutations have never been reported in families with normosmic IHH (nIHH) or in families with both anosmic and nonanosmic individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372819968\">",
"    <span class=\"h2\">",
"     FGFR1 (KAL2 gene)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular origin of an autosomal dominant form of Kallmann syndrome (KS) was identified by loss-of-function mutations of the fibroblast growth factor-1 receptor (FGFR1) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/21\">",
"     21",
"    </a>",
"    ]. In that series, heterozygous FGFR1 mutations were found in four familial cases and in eight sporadic cases. In addition to cleft palate, the only patient in the series who harbored a homozygous mutation was found to have agenesis of the corpus callosum, unilateral hearing loss, and fusion of the fourth and fifth metacarpal bones. In these cases, there was considerable variability in the lack of sense of smell within a given family and a broad range of both testicular sizes and endogenous LH pulses prior to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interestingly, the protein products of KAL1 and FGFR1 seem to interact functionally: the anosmin protein may facilitate the signaling of fibroblast growth factor through its receptor, FGFR1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/22\">",
"     22",
"    </a>",
"    ]. As the KAL1 gene can partially escape X-inactivation, it has been proposed that a higher production of anosmin in females may rescue FGFR1 signaling in certain cases of haploinsufficiency, thus explaining the higher prevalence of the disease in males.",
"   </p>",
"   <p>",
"    In addition, mutations in FGFR1 not only cause normosmic idiopathic hypogonadotropic hypogonadism (nIHH) but also KS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/23\">",
"     23",
"    </a>",
"    ]. Other genes in the FGF signaling pathway, such as FGF8 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/24\">",
"     24",
"    </a>",
"    ], when mutated, can also cause KS and nIHH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372819990\">",
"    <span class=\"h2\">",
"     FGF8",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, FGF8 was uncovered as a critical ligand for FGFR1 in GnRH ontogeny [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/25\">",
"     25",
"    </a>",
"    ]. Subjects harboring FGF8 mutations similarly display a broad spectrum of pubertal development ranging from absent to partial to complete puberty (in a male with adult onset hypogonadotropic hypogonadism). Their associated nonreproductive phenotypes include hearing loss and a range of skeletal features (high arched palate, cleft",
"    <span class=\"nowrap\">",
"     lip/palate,",
"    </span>",
"    severe osteoporosis, camptodactyly, and hyperlaxity of the digits) and variable expressivity among family members is evident in family members harboring the identical mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372819997\">",
"    <span class=\"h2\">",
"     Prokineticin 2 (PROK2) and prokineticin receptor 2 (PROKR2) mutations (KAL3 and KAL4)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in both this ligand and receptor pair have now been associated with both KS and nIHH. The unusual feature of these mutations is that while homozygous mutations do occur, the mutations in the ligand and receptor in these series are most typically heterozygous, a genetic puzzle since the animal model of this syndrome is typically autosomal recessive in nature [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Given the increasing evidence of oligogenic inheritance in this condition, this finding implies that other as-yet-to be-described genes may well be mutated in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372820004\">",
"    <span class=\"h2\">",
"     Kisspeptin 1 receptor gene (KISS1R, formerly GPR54)",
"    </span>",
"    &nbsp;&mdash;&nbsp;IHH due to mutations in the GPR54 gene (which is located on chromosome 19p13.3 and encodes the G-protein coupled receptor-54) has been reported in individuals from a large consanguineous family and from an unrelated patient with sporadic IHH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/29\">",
"     29",
"    </a>",
"    ]. Another group reported similar GPR54 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How these mutations might lead to IHH was assessed in a Gpr54-deficient mouse model that resulted in a phenotype similar to that in humans (ie, IHH that was responsive to exogenous GnRH) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/29\">",
"     29",
"    </a>",
"    ]. The mice had normal hypothalamic GnRH content, suggesting that GnRH neurons are present in the hypothalamus and can synthesize the peptide, but that GPR54 is necessary for processing or secretion of GnRH. These observations suggest that the GPR54 gene may be an important gatekeeper gene for puberty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ligand for GPR54 has been identified by both experimental and bioinformatic approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/30\">",
"     30",
"    </a>",
"    ]. Kisspeptin is a 145 amino acid precursor that after cleavage gives rise to a 54 amino acid product termed metastin, so-called because of its ability to suppress metastases in vitro in various tumor cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In animal models, this",
"    <span class=\"nowrap\">",
"     ligand/receptor",
"    </span>",
"    combination",
"    <span class=\"nowrap\">",
"     (metastin/GPR54)",
"    </span>",
"    can advance puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/34\">",
"     34",
"    </a>",
"    ] and can overcome the amenorrhea of congenital leptin and leptin receptor deficiency, and starvation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/35\">",
"     35",
"    </a>",
"    ]. Gain-of-function mutations in the Kisspeptin 1 gene (KISS1) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/36\">",
"     36",
"    </a>",
"    ] and Kisspeptin 1 receptor (KISS1R) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/37\">",
"     37",
"    </a>",
"    ] have been implicated in the pathogenesis of some cases of GnRH-dependent precocious puberty. Thus, it is becoming clear that this system is a major gatekeeper of the pubertal process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H430022015\">",
"    <span class=\"h3\">",
"     Kisspeptin1 gene (KISS1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, inactivating mutations in the kisspeptin1 receptor gene may result in idiopathic hypogonadotropic hypogonadism (IHH). In addition, loss-of-function mutations in the kisspeptin1 gene have now been identified in four sisters from a large consanguineous family [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372820011\">",
"    <span class=\"h2\">",
"     GnRH receptor mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of hypogonadotropic hypogonadism are caused by loss-of-function mutations in the GnRH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In a series of 48 probands with IHH, two of five patients with normosmic, autosomal recessive IHH had GnRH receptor mutations, while 3 of 18 patients with normosmic sporadic IHH had such mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with hypogonadism caused by inactivating mutations of the GnRH receptor tend to have a poor response to pulsatile GnRH administration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/6\">",
"     6",
"    </a>",
"    ]. However, successful ovulation and conception have been described in a patient with an inactivating receptor mutation receiving high doses of pulsatile GnRH, thus indicating that many GnRH receptor mutations create a relative rather than an absolute resistance to pulsatile GnRH administration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372820047\">",
"    <span class=\"h2\">",
"     GnRH1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of GNRH1, the gene that encodes the preprohormone that is processed to GnRH, have also been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The phenotype is that of nIHH and, like mutations in the GPR54 receptor, does not include patients with anosmia.",
"   </p>",
"   <p>",
"    In one report, a teenage brother and sister who both had severe normosmic hypogonadotropic hypogonadism were found to have a frameshift mutation in GNRH1 that resulted in a protein precursor that lacked the GnRH sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/43\">",
"     43",
"    </a>",
"    ]. In a second study of 310 patients with nIHH, one male with severe hypogonadism had a frameshift mutation that predicted the presence of a stop codon, and four patients had heterozygous mutations not seen in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372820061\">",
"    <span class=\"h2\">",
"     Tachykinin 3 (TAC3) and tachykinin 3 receptor (TAC3R) mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in TAC3 and TAC3R (encoding neurokinin B and its receptor) have been reported. The tachykinins are a family of neurosecretory peptides; TAC3 is secreted by the same neurons that secrete kisspeptin, the ligand for GPR54. In one study of an inbred Turkish population, mutations in both its receptor and ligand were identified that caused an autosomal recessive from of normosmic idiopathic hypogonadotropic hypogonadism (nIHH) (similar to GPR54 mutations) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/45\">",
"     45",
"    </a>",
"    ]. In subsequent studies, however, while it seems that the Turkish population has a higher incidence of this mutated gene as a cause of the syndrome in this endogamous population, this gene causes isolated GnRH deficiency in several other populations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, these patients have the relatively unique phenotypes of microphallus and cryptorchidism in males, as well as reversibility during adulthood in both males and females [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/47\">",
"     47",
"    </a>",
"    ]. Taken together, this clinical finding may imply that the Neurokinin B pathway may well be more critical during the neonatal period and perhaps less critical during the adolescence and adult periods of development and functioning of the GnRH neurons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446615073\">",
"    <span class=\"h2\">",
"     CHD7",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of Kallmann syndrome (hypogonadotropic hypogonadism and",
"    <span class=\"nowrap\">",
"     anosmia/hyposmia)",
"    </span>",
"    are often present in patients with CHARGE syndrome (a syndrome caused by mutations in the CHD7 gene). CHD7 mutations have now been identified in individuals with Kallmann syndrome, some of whom had additional features of CHARGE syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. We therefore recommend that patients with Kallmann syndrome be screened for clinical features suggestive of CHARGE syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Typical findings include coloboma of the eye, dysmorphic ears, hearing loss, delayed growth and development, and congenital heart defects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446615142\">",
"    <span class=\"h2\">",
"     Semaphorin 3A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss-of-function mutations in the SEMA3A gene, which codes for semaphorin 3A, a protein important for GnRH neuronal migration, have been identified in patients with Kallmann syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372820068\">",
"    <span class=\"h2\">",
"     Digenic mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although IHH has been considered to be a monogenic disorder, phenotypic variability within and across families with single gene defects suggests that in some cases there may be additional gene defects. This was illustrated in a report of two families with IHH (one anosmic and one normosmic pedigree) in whom two mutations were found [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A heterozygous FGFR1 mutation and heterozygous deletion in the NELF gene in the anosmic pedigree.",
"     </li>",
"     <li>",
"      A compound heterozygous GnRHR mutation and heterozygous FGFR1 mutation in the normosmic pedigree.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent study of nearly 400 patients with isolated GnRH deficiency who had their full exomic sequences determined for the eight then known genes causing this syndrome, the following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A heterozygosity of 10 percent of coding sequence mutations in many of the genes causing isolated GnRH deficiency in the normal control populations in the absence of any phenotype.",
"     </li>",
"     <li>",
"      An incidence of 17 percent in all cases of this condition.",
"     </li>",
"     <li>",
"      Of the 88 patients with a demonstrable defect in a single gene known to cause this disease, 10 (11 percent) harbored a previously unsuspected second mutation (ie, &ldquo;second hit&rdquo; genetically).",
"     </li>",
"     <li>",
"      Considering that only about 30 percent of cases of this disease were known, it is reasonable to suspect that the two-thirds of familial cases are likely to exhibit a similar if not higher incidence of digenic inheritance.",
"     </li>",
"     <li>",
"      Multiple gene involvement accounts for much of the variable phenotypic expressivity, as evidenced by the observation that the identical mutation in patients both within and across families can result in variable phenotypes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital GnRH deficiency primarily is a disease of males, with the male-to-female ratio being approximately 5:1, and can present at any age. The presenting signs and symptoms are a function of the age-related period of reproductive activity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the neonatal period, boys with GnRH deficiency can present with micropenis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cryptorchidism due to the silence of their hypothalamic-pituitary-gonadal axis during this period; approximately one-half of boys with microphallus have isolated GnRH deficiency as the underlying diagnosis. In comparison, newborn girls have no obvious abnormal findings that might provide clues to the diagnosis.",
"     </li>",
"     <li>",
"      During childhood, which is physiologically characterized by a latency period of reproductive activity, the lack of sense of smell in some patients (anosmia) or the presence of skeletal abnormalities such as cleft",
"      <span class=\"nowrap\">",
"       lip/cleft",
"      </span>",
"      palate or syndactyly (in patients with mutations in the FGF signalling pathway) generally are the only way the diagnosis can be made. This association of IHH with anosmia is referred to as Kallmann Syndrome.",
"     </li>",
"     <li>",
"      At puberty, patients of both sexes can present with a variable failure to undergo sexual maturation and establish a clear-cut growth spurt (eg, primary amenorrhea in girls). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"       \"Diagnosis and treatment of delayed puberty\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients undergo some degree of pubertal development that then ceases. A few have completely normal pubertal development only to develop hypogonadotropism subsequently in adulthood, leading to infertility and sexual dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/53\">",
"       53",
"      </a>",
"      ]. These patients are referred to as having the adult-onset or acquired form of IHH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"       \"Clinical features and diagnosis of male hypogonadism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The body habitus of adolescent patients failing to undergo puberty often is eunuchoidal, with arm span exceeding height by 5 cm or more. This finding reflects the delayed closure of the epiphyses of long bones caused by hypogonadism during puberty.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women, secondary sexual characteristics are often completely absent, with little or no breast development or axillary hair.",
"     </li>",
"     <li>",
"      Men have little or no beard and body hair development, no increase in bulk of the muscles, and failure of the voice to deepen.",
"     </li>",
"     <li>",
"      In both sexes, some pubic hair can be present because adrenarche, with its concomitant small amounts of adrenal androgen and estrogen secretion, is characteristically normal. In fact, if adrenal function is not normal (DHEA-S being the best single test of adrenal maturation), the clinician should investigate other causes of this condition such as DAX deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/54\">",
"       54",
"      </a>",
"      ]. In comparison, both adrenarche and the normal growth spurt are attenuated in constitutional delay of puberty, which is otherwise difficult to distinguish from GnRH deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"       \"Diagnosis and treatment of delayed puberty\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While testicular volume is typically prepubertal (ie, &lt;4 mL), a discrete subset of men with congenital GnRH deficiency can have normal adult-size testes (&gt;12 to 15 mL) and even demonstrate sperm in the presence of a small ejaculate volume (a typically androgen-dependent component of the semen analysis). This combination of relatively well preserved seminiferous tubular development, normal size of testes, and spermatogenesis in the presence of deficient LH-Leydig cell secretion of testosterone is referred to as the &ldquo;fertile eunuch variant&rdquo; of idiopathic hypogonadotropic hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/55\">",
"     55",
"    </a>",
"    ]. Spontaneous recovery has also been described in one fertile eunuch patient with a GnRH receptor mutation and now in patients with loss-of-function mutations in the fibroblast growth factor receptor 1 (FGFR1) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H372819968\">",
"     'FGFR1 (KAL2 gene)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For most patients, the mechanisms responsible for complete Leydig cell failure with its attendant eunuchoidism and relative preservation of seminiferous tubular function are poorly understood. This variant does, however, illustrate the relatively broad spectrum of clinical expression that can occur in GnRH deficiency, ranging from complete absence of sexual development to near normal completion of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gynecomastia is not typically a feature of GnRH deficiency. The total absence of gonadotropins results in low testicular aromatase activity and, therefore, little estrogen production.",
"   </p>",
"   <p>",
"    Several congenital abnormalities can be found in patients with congenital GnRH deficiency. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mid-line defects (ie, cleft",
"      <span class=\"nowrap\">",
"       lip/palate)",
"      </span>",
"     </li>",
"     <li>",
"      Unilateral renal agenesis",
"     </li>",
"     <li>",
"      Uni- or bilateral cryptorchidism",
"     </li>",
"     <li>",
"      Syndactyl or other skeletal abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hyposmia or anosmia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of normosmia with congenital GnRH deficiency is called idiopathic hypogonadotropic hypogonadism (IHH) or normosmic IHH (nIHH); with anosmia, it is termed Kallmann syndrome (KS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one large series of patients with IHH, unilateral renal agenesis and synkinesia (mirror movements) appeared to be phenotypic markers for the X-linked form of Kallmann syndrome (see below), although these non-reproductive phenotypic manifestations of the syndrome are quite variable and the documentation of a defect in the KAL1 gene may be lacking in the literature due to its relative expense. Of note, the reproductive manifestations of the X-linked form of Kallmann syndrome are more consistent; ie, prepubertal testes size and complete absence of GnRH-induced LH pulsations during frequency sampling studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/18,59\">",
"     18,59",
"    </a>",
"    ]. However, synkinesia has now also been reported in one family with an autosomal dominant form of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/21\">",
"     21",
"    </a>",
"    ]. In this regard, the X-linked form of this condition with genetic defects in the KAL1 gene have the most consistent phenotypic presentations of all of the genes associated with this condition.",
"   </p>",
"   <p>",
"    In the absence of anomalies like those described above and response to exogenous GnRH, patients with congenital GnRH deficiency cannot be distinguished clinically from patients with inactivating mutations of the GnRH receptor or those with mutations of the gonadotroph cells resulting in production of gonadotropins with decreased biological activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When suspected on the basis of the clinical presentation or physical findings, the diagnosis of congenital GnRH deficiency should be confirmed biochemically. The diagnosis requires the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The demonstration of prepubertal serum concentrations of sex steroid hormones (serum testosterone less than 100",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (3.5",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      in males or serum estradiol less than 20",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      [73",
"      <span class=\"nowrap\">",
"       pmol/L]",
"      </span>",
"      in females).",
"     </li>",
"     <li>",
"      Low or normal serum LH and FSH concentrations (usually less than 4 to 5",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      rather than the high concentrations expected with primary gonadal failure.",
"     </li>",
"     <li>",
"      Otherwise normal anterior pituitary function.",
"     </li>",
"     <li>",
"      Normal appearance of the hypothalamus and pituitary region on MRI; when seeking this diagnosis, it is useful to request fine (1 mm) cuts through the olfactory bulb region of the MRI to define subtle abnormalities of the olfactory system that may signal which genetic tests to request first.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients fulfilling the above laboratory criteria, the main (and most difficult) differential diagnosis is with delayed puberty. A definitive diagnosis of congenital GnRH deficiency in the absence of a family history or prior genetic testing is difficult to make until the patient reaches at least 18 years of age, unless other suggestive features are present (ie, prior microphallus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cryptorchism, anosmia, renal agenesis, skeletal defects, etc). Constitutional delay of puberty is far more common than congenital GnRH deficiency, whereas the incidence of congenital GnRH deficiency is uncertain, but low, with estimates ranging between 1 in 10,000 to 86,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No single test can reliably distinguish between these two disorders until more widespread genetic testing becomes available and, therefore, one has to rely on an array of clinical clues as well as on the natural evolution over time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A family history of GnRH deficiency, anosmia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of one or several associated congenital abnormalities suggests congenital GnRH deficiency.",
"     </li>",
"     <li>",
"      A history of \"stalled\" puberty rather than total absence of development, a family history of delayed puberty, or early evidence of breast or testicular development are useful indicators that puberty is likely to occur spontaneously.",
"     </li>",
"     <li>",
"      Nongonadal manifestations of Kallmann syndrome, such as anosmia, cleft",
"      <span class=\"nowrap\">",
"       lip/palate,",
"      </span>",
"      urogenital tract abnormalities, or syndactyly suggest that syndrome.",
"     </li>",
"     <li>",
"      The presence of pubic hair suggests congenital GnRH deficiency because normal adrenarche still occurs; in comparison, both adrenarche and the normal growth spurt are attenuated in constitutional delay of puberty, and pubic hair typically is absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When GnRH deficiency presents after puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/53\">",
"     53",
"    </a>",
"    ], other causes of secondary hypogonadism (particularly tumors of the hypothalamic-pituitary axis) must be eliminated, as this is really a diagnosis of exclusion (",
"    <a class=\"graphic graphic_table graphicRef61467 \" href=\"UTD.htm?23/44/24268\">",
"     table 1",
"    </a>",
"    ). Tumors occasionally can be suspected by the presence of other neurologic symptoms (headaches, visual disturbances) or the demonstration of other defects in anterior pituitary hormone secretion on initial biochemical screening. However, enlarging mass lesions in either the pituitary or the central nervous system decrease the secretion of corticotropin (ACTH) or thyrotropin (TSH) less than that of gonadotropins or growth hormone. Similarly, hemochromatosis should be eliminated by appropriate testing of iron, iron binding capacity, and ferritin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three treatments for patients with congenital GnRH deficiency are available: gonadal steroid hormones, human gonadotropins, and GnRH. The choice of therapy depends upon the patient's desire to achieve one or more of the following goals:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To develop secondary sex characteristics",
"     </li>",
"     <li>",
"      To build and sustain normal bone and muscle mass",
"     </li>",
"     <li>",
"      To restore fertility",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hormone replacement",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Girls and women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous estrogens are used to start secondary sexual development in prepubertal girls. Initiation of treatment should be based upon the patient's bone age, current height percentiles, psychosexual needs, and predicted adult height. The shorter the predicted adult height, the later puberty should be induced. Inappropriate use of estrogens may result in rapid osseous maturation with resulting short stature and irregular menstrual bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and treatment of delayed puberty\", section on 'Estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initiation of puberty can begin with any type or route of exogenous estrogen, oral or transdermal. One traditional regimen that has been used is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"     conjugated equine estrogens",
"    </a>",
"    0.3 mg per day increasing to 1.25 mg per day, or the lowest dose that produces normal menses. Initial therapy should consist of estrogen alone to maximize breast growth and to induce uterine and endometrial proliferation. Initiation of puberty with transdermal 17-&szlig;-estradiol, 0.08 to 0.12 mcg estradiol per kg body weight, is also successful [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/61\">",
"     61",
"    </a>",
"    ], and is commonly prescribed by pediatricians. A progestin eventually needs to be added to prevent endometrial hyperplasia, but adding it prematurely or administering combinations of estrogens and progestins (eg, birth control pills) before completion of breast development should be avoided because it is likely to reduce ultimate breast size. Additional details on progestin therapy and maintenance hormone therapy are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and treatment of delayed puberty\", section on 'Estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Boys and men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone therapy is indicated when the development of secondary sexual characteristics is the only goal (which is usual in pubertal boys). Oral testosterone preparations should be avoided because of hepatic toxicity. The choices for testosterone replacement include daily applications of testosterone gels and intramuscular injections of long-acting testosterone preparations. A more detailed discussion of this issue, including specific recommendations for monitoring, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whichever form of testosterone replacement is chosen, providing psychological support is important because the patient will have a variety of new and often confusing symptoms, much like an adolescent undergoing puberty but more difficult because it will likely be at a later age. Testosterone therapy for delayed puberty and male hypogonadism is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fertility",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ovulation induction in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;When fertility is desired, administration of either pulsatile GnRH or exogenous gonadotropins results in ovulation in 95 percent of women. A full evaluation of tubal patency and a semen analysis in the male partner should be performed before undertaking gonadotropin therapy with its attendant risks and costs. Pulsatile administration of exogenous GnRH is an effective therapy for the stimulation of endogenous gonadotropin secretion, follicular development, and ovulation in women with GnRH deficiency. The resulting serum FSH and LH concentrations remain within the normal range and the chances of multifollicular development and ovarian hyperstimulation are therefore low [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/62\">",
"     62",
"    </a>",
"    ]. Pulsatile GnRH is available in some countries, but not the US. Gonadotropin therapy is an effective alternative. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Induction of spermatogenesis in men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone replacement alone does not restore normal spermatogenesis in men with GnRH deficiency. The traditional approach to inducing spermatogenesis in men with hypogonadotropic hypogonadism is the conjoint administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG) to induce full steroidogenesis from Leydig cells and menopausal gonadotropins (cheaper) or recombinant FSH to induce spermatogenesis (",
"    <a class=\"graphic graphic_figure graphicRef54583 \" href=\"UTD.htm?33/18/34094\">",
"     figure 4",
"    </a>",
"    ). This is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=see_link\">",
"     \"Induction of fertility in men with secondary hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulsatile GnRH therapy is an effective but currently unapproved treatment for GnRH-deficient men seeking fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/5,53,63\">",
"     5,53,63",
"    </a>",
"    ]. The importance of pulsatile secretion is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .) GnRH is administered subcutaneously at two-hour intervals via a portable mini-pump that infuses GnRH over 60 seconds. This frequency is set at the frequency of endogenous GnRH-induced LH pulses in normal men (every 120 minutes).",
"   </p>",
"   <p>",
"    Treatment is begun at a dose of 25",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per bolus and adjusted upward on the basis of the serum testosterone concentration. When normal values have been achieved, the dose is held constant and measurement of testicular size and seminal fluid analysis are performed at monthly intervals.",
"   </p>",
"   <p>",
"    Induction of spermatogenesis can take one to two years during normal puberty. Thus, pulsatile GnRH therapy must be given for an equivalent period depending upon the pretreatment gonadal size. Men with infantile testes (eg, 1 to 3 mL) or a past history of cryptorchidism require the longest durations of therapy, whereas those with larger testicular size respond sooner, as they do when treated with hCG and recombinant FSH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/5,63\">",
"     5,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulsatile GnRH and gonadotropin therapy have been compared directly. Pulsatile GnRH results in more testicular growth than do gonadotropins. However, they do not seem to have any difference in the induction of spermatogenesis, which occurs in approximately 90 to 95 percent of men with either approach [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. At present, the number of patients who have been studied after pulsatile GnRH therapy is quite limited [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/20,67\">",
"     20,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic failures with GnRH therapy are uncommon, but can occur in men with unresponsive pituitaries (eg, due to hemochromatosis) or secondary failures coincident with the development of antibodies to GnRH. The latter is a rare occurrence and generally occurs in the setting of intermittent or discontinuous therapy. Additionally, rare instances of failure to respond to GnRH therapy have uncovered additional defects in the hypothalamic-pituitary-gonadal axis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94286031\">",
"    <span class=\"h2\">",
"     Reversal of IHH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic hypogonadotropic hypogonadism was previously thought to be a permanent disorder requiring life-long therapy. However, reversal of the disorder has been reported in approximately 10 percent of male patients after discontinuation of hormonal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a report of 15 male patients (mean age 21 years), 10 of whom were identified retrospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/7/2170/abstract/70\">",
"     70",
"    </a>",
"    ]. The other five patients were identified prospectively among 50 men with IHH (10 percent) at a mean of six &plusmn; three weeks after discontinuation of therapy. Sustained reversal of IHH was defined as the presence of normal adult testosterone levels after hormonal therapy was discontinued.",
"   </p>",
"   <p>",
"    The rate of reversal was similar for men who had absent or partial puberty at initial presentation. Mean testicular volume and serum total testosterone concentrations increased into the normal adult male range, and both pulsatile LH secretion and spermatogenesis were documented. These findings were noted. At least 13 of the 15 patients had persistent reversal at an average of 6.5 years after reversal.",
"   </p>",
"   <p>",
"    Based upon these observations, we suggest the following approach in men with IHH. For men who have achieved normal testicular volume while being treated with testosterone alone (which is often the initial treatment when fertility is not yet desired), we recommend that testosterone treatment be discontinued and serum testosterone be determined after two to three months. The rationale is that testosterone treatment will not directly increase testicular size and therefore the increase is probably the result of endogenous gonadotropin secretion. For men who have achieved adult reproductive parameters (testicular volume, serum testosterone concentrations, and sperm in the ejaculate) during treatment with gonadotropins or GnRH, hormonal therapy could be discontinued for two to three months if the patient wishes to evaluate for possible reversibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111576533\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital gonadotropin-releasing hormone (GnRH) deficiency refers to the functional absence of GnRH secretion from hypothalamic hypophysiotropic neurons or a defect in its action at the level of the gonadotrope in the case of mutations in the GnRH receptor. This defect results in idiopathic hypogonadotropic (secondary) hypogonadism (IHH) and is its most common cause.",
"     </li>",
"     <li>",
"      Congenital GnRH deficiency (with or without anosmia) can be inherited as an autosomal dominant, autosomal recessive, or X-linked condition. Increasingly, however, oligogenic inheritance is being appreciated that is manifested by incomplete penetrance and variable expressivity within families sharing at least one mutation in a gene recognized to be critical for GnRH secretion. (See",
"      <a class=\"local\" href=\"#H372819954\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To date, a number of genes have been implicated in the etiology of congenital GnRH deficiency: KAL1 gene, FGF8 and FGFR1 (KAL2 gene), Prokineticin 2 (PROK2) and prokineticin receptor 2 (PROKR2) mutations (KAL3 and KAL4), Kisspeptin and KISS1 receptor (formerly GPR54 gene), GnRH1 and GnRH receptor mutations, Tachykinin 3 (TAC3) and tachykinin 3 receptor (TAC3R) mutations, and CHD7 and semaphorin 3A. (See",
"      <a class=\"local\" href=\"#H372819954\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital GnRH deficiency is primarily a disease of males, with the male-to-female ratio of approximately 5:1. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main differential diagnosis is delayed puberty and a definitive diagnosis of congenital GnRH deficiency in the absence of a family history or prior genetic testing is difficult to make until the patient reaches at least 18 years of age, unless other suggestive features are present (ie, prior microphallus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cryptorchism, anosmia, renal agenesis, skeletal defects, etc). Constitutional delay of puberty is far more common than congenital GnRH deficiency, whereas the incidence of congenital GnRH deficiency is uncertain, but low, with estimates ranging between 1 in 10,000 to 86,000. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The management of GnRH deficiency includes replacing sex steroids to develop secondary sex characteristics, and to build and sustain normal bone and muscle mass. Pulsatile GnRH and exogenous gonadotropin therapy are used for ovulation induction in women and for induction of spermatogenesis in men. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/1\">",
"      de Roux N, Young J, Brailly-Tabard S, et al. The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred. J Clin Endocrinol Metab 1999; 84:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/2\">",
"      Phillip M, Arbelle JE, Segev Y, Parvari R. Male hypogonadism due to a mutation in the gene for the beta-subunit of follicle-stimulating hormone. N Engl J Med 1998; 338:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/3\">",
"      Valdes-Socin H, Salvi R, Daly AF, et al. Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene. N Engl J Med 2004; 351:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/4\">",
"      Spratt DI, Carr DB, Merriam GR, et al. The spectrum of abnormal patterns of gonadotropin-releasing hormone secretion in men with idiopathic hypogonadotropic hypogonadism: clinical and laboratory correlations. J Clin Endocrinol Metab 1987; 64:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/5\">",
"      Hoffman AR, Crowley WF Jr. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982; 307:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/6\">",
"      Caron P, Chauvin S, Christin-Maitre S, et al. Resistance of hypogonadic patients with mutated GnRH receptor genes to pulsatile GnRH administration. J Clin Endocrinol Metab 1999; 84:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/7\">",
"      Pitteloud N, Quinton R, Pearce S, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest 2007; 117:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/8\">",
"      Sykiotis GP, Plummer L, Hughes VA, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci U S A 2010; 107:15140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/9\">",
"      Prager O, Braunstein GD. X-chromosome-linked Kallmann's syndrome: pathology at the molecular level. J Clin Endocrinol Metab 1993; 76:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/10\">",
"      Schwanzel-Fukuda M, Bick D, Pfaff DW. Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Brain Res Mol Brain Res 1989; 6:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/11\">",
"      Schwanzel-Fukuda M, Pfaff DW. Origin of luteinizing hormone-releasing hormone neurons. Nature 1989; 338:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/12\">",
"      Soussi-Yanicostas N, de Castro F, Julliard AK, et al. Anosmin-1, defective in the X-linked form of Kallmann syndrome, promotes axonal branch formation from olfactory bulb output neurons. Cell 2002; 109:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/13\">",
"      Legouis R, Hardelin JP, Levilliers J, et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991; 67:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/14\">",
"      Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991; 353:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/15\">",
"      Hardelin JP, Levilliers J, Blanchard S, et al. Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome. Hum Mol Genet 1993; 2:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/16\">",
"      Georgopoulos NA, Pralong FP, Seidman CE, et al. Genetic heterogeneity evidenced by low incidence of KAL-1 gene mutations in sporadic cases of gonadotropin-releasing hormone deficiency. J Clin Endocrinol Metab 1997; 82:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/17\">",
"      Oliveira LM, Seminara SB, Beranova M, et al. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab 2001; 86:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/18\">",
"      Pitteloud N, Hayes FJ, Boepple PA, et al. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002; 87:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/19\">",
"      Salenave S, Chanson P, Bry H, et al. Kallmann's syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations. J Clin Endocrinol Metab 2008; 93:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/20\">",
"      Pitteloud N, Hayes FJ, Dwyer A, et al. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002; 87:4128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/21\">",
"      Dod&eacute; C, Levilliers J, Dupont JM, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003; 33:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/22\">",
"      Gonz&aacute;lez-Mart&iacute;nez D, Kim SH, Hu Y, et al. Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism. J Neurosci 2004; 24:10384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/23\">",
"      Pitteloud N, Acierno JS Jr, Meysing A, et al. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A 2006; 103:6281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/24\">",
"      Falardeau, J, Chung, W, Beenken, W, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice J Clin Invest 2008; 118: 2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/25\">",
"      Falardeau J, Chung WC, Beenken A, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008; 118:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/26\">",
"      Trarbach EB, Abreu AP, Silveira LF, et al. Nonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiency. J Clin Endocrinol Metab 2010; 95:3491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/27\">",
"      Dod&eacute;, C, Teixeira, L, Levilliers, J, et al. Kallmann Syndrome: Mutations in the Genes Encoding Prokineticin-2 and Prokineticin Receptor-2. Plos Genetics 2006; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/28\">",
"      Cole LW, Sidis Y, Zhang C, et al. Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab 2008; 93:3551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/29\">",
"      Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/30\">",
"      de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 2003; 100:10972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/31\">",
"      Miele ME, Robertson G, Lee JH, et al. Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes 1 or 6. Mol Carcinog 1996; 15:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/32\">",
"      Lee, JH, Welch, DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997; 15:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/33\">",
"      Lee JH, Miele ME, Hicks DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996; 88:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/34\">",
"      Navarro VM, Fern&aacute;ndez-Fern&aacute;ndez R, Castellano JM, et al. Advanced vaginal opening and precocious activation of the reproductive axis by KiSS-1 peptide, the endogenous ligand of GPR54. J Physiol 2004; 561:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/35\">",
"      Castellano JM, Navarro VM, Fern&aacute;ndez-Fern&aacute;ndez R, et al. Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition. Endocrinology 2005; 146:3917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/36\">",
"      Silveira LG, Noel SD, Silveira-Neto AP, et al. Mutations of the KISS1 gene in disorders of puberty. J Clin Endocrinol Metab 2010; 95:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/37\">",
"      Teles MG, Bianco SD, Brito VN, et al. A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med 2008; 358:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/38\">",
"      Topaloglu AK, Tello JA, Kotan LD, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med 2012; 366:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/39\">",
"      de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997; 337:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/40\">",
"      Pralong FP, Gomez F, Castillo E, et al. Complete hypogonadotropic hypogonadism associated with a novel inactivating mutation of the gonadotropin-releasing hormone receptor. J Clin Endocrinol Metab 1999; 84:3811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/41\">",
"      Beranova M, Oliveira LM, B&eacute;d&eacute;carrats GY, et al. Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2001; 86:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/42\">",
"      Seminara SB, Beranova M, Oliveira LM, et al. Successful use of pulsatile gonadotropin-releasing hormone (GnRH) for ovulation induction and pregnancy in a patient with GnRH receptor mutations. J Clin Endocrinol Metab 2000; 85:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/43\">",
"      Bouligand J, Ghervan C, Tello JA, et al. Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med 2009; 360:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/44\">",
"      Chan YM, de Guillebon A, Lang-Muritano M, et al. GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A 2009; 106:11703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/45\">",
"      Topaloglu AK, Reimann F, Guclu M, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 2009; 41:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/46\">",
"      Young J, Bouligand J, Francou B, et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab 2010; 95:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/47\">",
"      Gianetti E, Tusset C, Noel SD, et al. TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab 2010; 95:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/48\">",
"      Bergman JE, de Ronde W, Jongmans MC, et al. The results of CHD7 analysis in clinically well-characterized patients with Kallmann syndrome. J Clin Endocrinol Metab 2012; 97:E858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/49\">",
"      Jongmans MC, van Ravenswaaij-Arts CM, Pitteloud N, et al. CHD7 mutations in patients initially diagnosed with Kallmann syndrome--the clinical overlap with CHARGE syndrome. Clin Genet 2009; 75:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/50\">",
"      Jongmans MC, Admiraal RJ, van der Donk KP, et al. CHARGE syndrome: the phenotypic spectrum of mutations in the CHD7 gene. J Med Genet 2006; 43:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/51\">",
"      Hanchate NK, Giacobini P, Lhuillier P, et al. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. PLoS Genet 2012; 8:e1002896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/52\">",
"      Young J, Metay C, Bouligand J, et al. SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development. Hum Reprod 2012; 27:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/53\">",
"      Nachtigall LB, Boepple PA, Pralong FP, Crowley WF Jr. Adult-onset idiopathic hypogonadotropic hypogonadism--a treatable form of male infertility. N Engl J Med 1997; 336:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/54\">",
"      El-Khairi R, Martinez-Aguayo A, Ferraz-de-Souza B, et al. Role of DAX-1 (NR0B1) and steroidogenic factor-1 (NR5A1) in human adrenal function. Endocr Dev 2011; 20:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/55\">",
"      Faiman C, Hoffman DL, Ryan RJ, Albert A. The \"fertile eunuch\" syndrome: demonstration of isolated luteinizing hormone deficiency by radioimmunoassay technique. Mayo Clin Proc 1968; 43:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/56\">",
"      Pitteloud N, Boepple PA, DeCruz S, et al. The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. J Clin Endocrinol Metab 2001; 86:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/57\">",
"      Pitteloud, N, Acierno, JS, Meysing, A, et al. Mutations in Fibroblast Growth Factor Receptor 1 cause both Kallmann Syndrome and normosmic idiopathic hypogonadotropic hypogonadism, Proceedings of the National Academy of Science 2006; 103:6281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/58\">",
"      Kallmann, FJ, Schoenfeld, WA, Barrera, SE. The genetic aspects of primary eunuchoidism. Am J Mental Defic 1944; 48:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/59\">",
"      Quinton R, Duke VM, Robertson A, et al. Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. Clin Endocrinol (Oxf) 2001; 55:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/60\">",
"      Seminara SB, Hayes FJ, Crowley WF Jr. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Endocr Rev 1998; 19:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/61\">",
"      Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab 2001; 86:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/62\">",
"      Martin KA, Hall JE, Adams JM, Crowley WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1993; 77:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/63\">",
"      Whitcomb RW, Crowley WF Jr. Clinical review 4: Diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men. J Clin Endocrinol Metab 1990; 70:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/64\">",
"      Kliesch S, Behre HM, Nieschlag E. High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. Eur J Endocrinol 1994; 131:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/65\">",
"      Liu L, Banks SM, Barnes KM, Sherins RJ. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1988; 67:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/66\">",
"      B&uuml;chter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998; 139:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/67\">",
"      Liu PY, Baker HW, Jayadev V, et al. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 2009; 94:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/68\">",
"      Sykiotis GP, Hoang XH, Avbelj M, et al. Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab 2010; 95:3019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/69\">",
"      Quinton R, Cheow HK, Tymms DJ, et al. Kallmann's syndrome: is it always for life? Clin Endocrinol (Oxf) 1999; 50:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/7/2170/abstract/70\">",
"      Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007; 357:863.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7465 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2170=[""].join("\n");
var outline_f2_7_2170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H111576533\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H372819954\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372819961\">",
"      KAL1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372819968\">",
"      FGFR1 (KAL2 gene)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372819990\">",
"      FGF8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372819997\">",
"      Prokineticin 2 (PROK2) and prokineticin receptor 2 (PROKR2) mutations (KAL3 and KAL4)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372820004\">",
"      Kisspeptin 1 receptor gene (KISS1R, formerly GPR54)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H430022015\">",
"      - Kisspeptin1 gene (KISS1)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372820011\">",
"      GnRH receptor mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372820047\">",
"      GnRH1 mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372820061\">",
"      Tachykinin 3 (TAC3) and tachykinin 3 receptor (TAC3R) mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H446615073\">",
"      CHD7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H446615142\">",
"      Semaphorin 3A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372820068\">",
"      Digenic mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hormone replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Girls and women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Boys and men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ovulation induction in women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Induction of spermatogenesis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROGNOSIS AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94286031\">",
"      Reversal of IHH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111576533\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7465\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7465|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/59/27582\" title=\"figure 1\">",
"      LH FSH lack in GnRH deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/9/16542\" title=\"figure 2\">",
"      LH response to pulsatile GnRH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/40/11918\" title=\"figure 3\">",
"      KALIG-1 gene in Kallmann syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/18/34094\" title=\"figure 4\">",
"      Spermatogenic response to gonadotropins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7465|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/44/24268\" title=\"table 1\">",
"      Causes secondary hypogonadism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=related_link\">",
"      Induction of fertility in men with secondary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_7_2171="IUD mechanism of action";
var content_f2_7_2171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible mechanisms of action of intrauterine devices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Changes in cervical mucus that inhibit sperm transport (eg,",
"increased copper concentration, thickening, glandular atrophy or",
"decidualization)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic inflammatory changes of the endometrium and fallopian",
"tubes, which have spermicidal effects and inhibit fertilization and",
"implantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thinning and glandular atrophy of the endometrium, which inhibits implantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direct ovicidal effects",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Stanford, JB, Mikolajczyk, RT. Am J Obstet Gynecol 2002; 187:1699.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2171=[""].join("\n");
var outline_f2_7_2171=null;
var title_f2_7_2172="MSKCC progn strat IFN response";
var content_f2_7_2172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Memorial Sloan Kettering prognostic stratification for response to interferon-alfa (INFa) for advanced RCC",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prognostic factors*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Median progression-free survival",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Median overall survival",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Overall survival (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        One year",
"       </td>",
"       <td class=\"subtitle2\">",
"        Two year",
"       </td>",
"       <td class=\"subtitle2\">",
"        Three year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 (low-risk)",
"       </td>",
"       <td>",
"        8.3 months",
"       </td>",
"       <td>",
"        30 months",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2 (intermediate-risk)",
"       </td>",
"       <td>",
"        5.1 months",
"       </td>",
"       <td>",
"        14 months",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 5 (high-risk)",
"       </td>",
"       <td>",
"        2.5 months",
"       </td>",
"       <td>",
"        5 months",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Poor prognostic factors:",
"     <br>",
"      <ul>",
"       <li>",
"        Karnofsky Performance Status (KPS) &lt;80 percent",
"       </li>",
"       <li>",
"        Serum lactate dehydrogenase (LDH) &gt;1.5 x upper limit of normal (ULN)",
"       </li>",
"       <li>",
"        Serum hemoglobin less than normal",
"       </li>",
"       <li>",
"        Serum calcium &gt;10 mg/dl",
"       </li>",
"       <li>",
"        Time from initial diagnosis to IFNa of &lt;1 year",
"       </li>",
"      </ul>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2172=[""].join("\n");
var outline_f2_7_2172=null;
var title_f2_7_2173="Molecular test transverse myelitis";
var content_f2_7_2173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular tests for infectious causes of transverse myelitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Availability*",
"       </td>",
"       <td class=\"subtitle1\">",
"        When inclusion of NAAT is indicated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preferred testing method(s)&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycoplasma spp",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT, serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacterium tuberculosis&Delta;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Potentially",
"       </td>",
"       <td>",
"        AFB stain, culture, histologic exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus (CMV)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT, preferably quantitative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus (EBV)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT, preferably quantitative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteroviruses",
"       </td>",
"       <td>",
"        Widespread",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex virus (HSV)",
"       </td>",
"       <td>",
"        Widespread",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mumps",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        History, viral culture, serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster virus (VZV)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        West Nile virus&loz;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Rarely (unless immunodeficient)",
"       </td>",
"       <td>",
"        Serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Spirochetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treponema pallidum (syphilis)",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Serology, CSF VDRL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schistosomiasis",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Serology, histologic exam",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; CDC: Centers for Disease Control and Prevention; NAAT: nucleic acid amplification testing; CSF: cerebrospinal fluid; AFB: acid fast bacilli.",
"     <br>",
"      * Widespread: readily available; Yes: consistently available, but not yet common; Limited: one or two specialized laboratories (eg, Centers for Disease Control and Prevention (CDC) or research groups).",
"      <br>",
"       &bull; Test on CSF except where noted.",
"       <br>",
"        &Delta; Limited experience, presumably poor sensitivity, high PPV.",
"        <br>",
"         &loz; Virus is usually cleared from blood and CSF prior to symptom onset.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2173=[""].join("\n");
var outline_f2_7_2173=null;
var title_f2_7_2174="X-linked recessive pedigree";
var content_f2_7_2174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Example of a pedigree demonstrating X-linked recessive inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that there are no affected females and that there is no male-to-male transmission.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of V Reid Sutton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2174=[""].join("\n");
var outline_f2_7_2174=null;
var title_f2_7_2175="Mucosal inflammation after FBA";
var content_f2_7_2175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airway foreign body in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: Peanut impacted in the right mainstem bronchus of a 13-month old child for four hours. Right: After 28 hours, the oily peanut has caused severe mucosal inflammation with bulky granulation tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_7_2175=[""].join("\n");
var outline_f2_7_2175=null;
